<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer - Kahale, LA - 2018 | Cochrane Library</title> <meta content="Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer - Kahale, LA - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006650.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer - Kahale, LA - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006650.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006650.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer" name="citation_title"/> <meta content="Lara A Kahale" name="citation_author"/> <meta content="American University of Beirut" name="citation_author_institution"/> <meta content="Maram B Hakoum" name="citation_author"/> <meta content="American University of Beirut" name="citation_author_institution"/> <meta content="Ibrahim G Tsolakian" name="citation_author"/> <meta content="American University of Beirut" name="citation_author_institution"/> <meta content="Fadel Alturki" name="citation_author"/> <meta content="American University of Beirut" name="citation_author_institution"/> <meta content="Charbel F Matar" name="citation_author"/> <meta content="American University of Beirut Medical Center" name="citation_author_institution"/> <meta content="Irene Terrenato" name="citation_author"/> <meta content="IRCCS Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Francesca Sperati" name="citation_author"/> <meta content="Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Maddalena Barba" name="citation_author"/> <meta content="IRCCS Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Victor ED Yosuico" name="citation_author"/> <meta content="Buffalo Medical Group" name="citation_author_institution"/> <meta content="Holger Schünemann" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Elie A Akl" name="citation_author"/> <meta content="American University of Beirut Medical Center" name="citation_author_institution"/> <meta content="ea32@aub.edu.lb" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD006650.pub5" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/06/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006650.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006650.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006650.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anticoagulants [adverse effects, *therapeutic use]; Azetidines [therapeutic use]; Benzimidazoles [therapeutic use]; Benzylamines [therapeutic use]; beta-Alanine [analogs &amp; derivatives, therapeutic use]; Dabigatran [therapeutic use]; Hemorrhage [chemically induced]; Heparin, Low-Molecular-Weight [therapeutic use]; Neoplasms [*complications]; Oligosaccharides [therapeutic use]; Randomized Controlled Trials as Topic; Venous Thromboembolism [*drug therapy, etiology, mortality]; Vitamin K [antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006650.pub5&amp;doi=10.1002/14651858.CD006650.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006650\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006650\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","fa","ko","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006650.pub5",title:"Anticoagulation for the long\\u2010term treatment of venous thromboembolism in people with cancer",firstPublishedDate:"Jun 19, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006650.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006650.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006650.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006650.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006650.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006650.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006650.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006650.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006650.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006650.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8718 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006650.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/appendices#CD006650-sec-0104"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/supinfo/CD006650StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/supinfo/CD006650StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0004">Lara A Kahale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0005">Maram B Hakoum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0006">Ibrahim G Tsolakian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0007">Fadel Alturki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0008">Charbel F Matar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0009">Irene Terrenato</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0010">Francesca Sperati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0011">Maddalena Barba</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0012">Victor ED Yosuico</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0013">Holger Schünemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information#CD006650-cr-0014"><i class="icon corresponding-author fa fa-envelope"></i>Elie A Akl</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information/en#CD006650-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 June 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006650.pub5">https://doi.org/10.1002/14651858.CD006650.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006650-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006650-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006650-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006650-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006650-abs-0007">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006650-abs-0001" lang="en"> <section id="CD006650-sec-0001"> <h3 class="title" id="CD006650-sec-0001">Background</h3> <p>Cancer increases the risk of thromboembolic events, especially in people receiving anticoagulation treatments. </p> </section> <section id="CD006650-sec-0002"> <h3 class="title" id="CD006650-sec-0002">Objectives</h3> <p>To compare the efficacy and safety of low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs), vitamin K antagonists (VKAs), and other anticoagulants for the long‐term treatment of venous thromboembolism (VTE) in people with cancer. </p> </section> <section id="CD006650-sec-0003"> <h3 class="title" id="CD006650-sec-0003">Search methods</h3> <p>We conducted a literature search including a comprehensive electronic search of the Cochrane Central Register of Controlled Trials ), MEDLINE (Ovid), and Embase (Ovid); handsearching conference proceedings; checking references of included studies;  and a search for ongoing studies in trial registries. As part of the living systematic review approach, we run searches continually, incorporating new evidence after it is identified. Last search date 14 May 2021. </p> </section> <section id="CD006650-sec-0004"> <h3 class="title" id="CD006650-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) assessing the benefits and harms of long‐term treatment with LMWHs, DOACs, VKAs, or other anticoagulants in people with cancer and symptomatic VTE. </p> </section> <section id="CD006650-sec-0005"> <h3 class="title" id="CD006650-sec-0005">Data collection and analysis</h3> <p>We extracted data in duplicate on study characteristics and risk of bias. Outcomes included: all‐cause mortality, recurrent VTE, major bleeding, minor bleeding, thrombocytopenia, and health‐related quality of life (QoL). We assessed the certainty of the evidence at the outcome level following the GRADE approach (GRADE handbook [GRADE handbook]). </p> </section> <section id="CD006650-sec-0006"> <h3 class="title" id="CD006650-sec-0006">Main results</h3> <p>Of 3583 citations,19 RCTs fulfilled the eligibility criteria.</p> <p><b>Low molecular weight heparins versus vitamin K antagonists</b><br/>Eight studies enrolling 2327 participants compared LMWHs with VKAs. Meta‐analysis of five studies probably did not rule out a beneficial or harmful effect of LMWHs compared to VKAs on mortality up to 12 months of follow‐up (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.88 to 1.13; risk difference (RD) 0 fewer per 1000, 95% CI 45 fewer to 48 more; moderate‐certainty evidence). Meta‐analysis of four studies did not rule out a beneficial or harmful effect of LMWHs compared to VKAs on major bleeding (RR 1.09, 95% CI 0.55 to 2.12; RD 4 more per 1000, 95% CI 19 fewer to 48 more, moderate‐certainty evidence) or minor bleeding (RR 0.78, 95% CI 0.47 to 1.27; RD 38 fewer per 1000, 95% CI 92 fewer to 47 more; low‐certainty evidence), or thrombocytopenia (RR 0.94, 95% CI 0.52 to 1.69). Meta‐analysis of five studies showed that LMWHs probably reduced the recurrence of VTE compared to VKAs (RR 0.58, 95% CI 0.43 to 0.77; RD 53 fewer per 1000, 95% CI 29 fewer to 72 fewer, moderate‐certainty evidence). </p> <p><b>Direct oral anticoagulants versus vitamin K antagonists</b><br/>Five studies enrolling 982 participants compared DOACs with VKAs. Meta‐analysis of four studies may not rule out a beneficial or harmful effect of DOACs compared to VKAs on mortality (RR 0.93, 95% CI 0.71 to 1.21; RD 12 fewer per 1000, 95% CI 51 fewer to 37 more; low‐certainty evidence), recurrent VTE (RR 0.66, 95% CI 0.33 to 1.31; RD 14 fewer per 1000, 95% CI 27 fewer to 12 more; low‐certainty evidence), major bleeding (RR 0.77, 95% CI 0.38 to 1.57, RD 8 fewer per 1000, 95% CI 22 fewer to 20 more; low‐certainty evidence), or minor bleeding (RR 0.84, 95% CI 0.58 to 1.22; RD 21 fewer per 1000, 95% CI 54 fewer to 28 more; low‐certainty evidence). One study reporting on DOAC versus VKA was published as abstract so is not included in the main analysis. </p> <p><b>Direct oral anticoagulants versus low molecular weight heparins</b><br/>Two studies enrolling 1455 participants compared DOAC with LMWH. The study by Raskob did not rule out a beneficial or harmful effect of DOACs compared to LMWH on mortality up to 12 months of follow‐up (RR 1.07, 95% CI 0.92 to 1.25; RD 27 more per 1000, 95% CI 30 fewer to 95 more; low‐certainty evidence). The data also showed that DOACs may have shown a likely reduction in VTE recurrence up to 12 months of follow‐up compared to LMWH (RR 0.69, 95% CI 0.47 to 1.01; RD 36 fewer per 1000, 95% CI 62 fewer to 1 more; low‐certainty evidence). DOAC may have increased major bleeding at 12 months of follow‐up compared to LMWH (RR 1.71, 95% CI 1.01 to 2.88; RD 29 more per 1000, 95% CI 0 fewer to 78 more; low‐certainty evidence) and likely increased minor bleeding up to 12 months of follow‐up compared to LMWH (RR 1.31, 95% CI 0.95 to 1.80; RD 35 more per 1000, 95% CI 6 fewer to 92 more; low‐certainty evidence). The second study on DOAC versus LMWH was published as an abstract and is not included in the main analysis. </p> <p><b>Idraparinux versus vitamin K antagonists</b><br/>One RCT with 284 participants compared once‐weekly subcutaneous injection of idraparinux versus standard treatment (parenteral anticoagulation followed by warfarin or acenocoumarol) for three or six months. The data probably did not rule out a beneficial or harmful effect of idraparinux compared to VKAs on mortality at six months (RR 1.11, 95% CI 0.78 to 1.59; RD 31 more per 1000, 95% CI 62 fewer to 167 more; moderate‐certainty evidence), VTE recurrence at six months (RR 0.46, 95% CI 0.16 to 1.32; RD 42 fewer per 1000, 95% CI 65 fewer to 25 more; low‐certainty evidence) or major bleeding (RR 1.11, 95% CI 0.35 to 3.56; RD 4 more per 1000, 95% CI 25 fewer to 98 more; low‐certainty evidence). </p> </section> <section id="CD006650-sec-0007"> <h3 class="title" id="CD006650-sec-0007">Authors' conclusions</h3> <p>For the long‐term treatment of VTE in people with cancer, evidence shows that LMWHs compared to VKAs probably produces an important reduction in VTE and DOACs compared to LMWH, may likely reduce VTE but may increase risk of major bleeding. Decisions for a person with cancer and VTE to start long‐term LMWHs versus oral anticoagulation should balance benefits and harms and integrate the person's values and preferences for the important outcomes and alternative management strategies. </p> <p>Editorial note: this is a living systematic review (LSR). LSRs offer new approaches to review updating in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006650-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006650-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006650-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006650-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006650-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006650-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006650-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006650-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006650-abs-0002" lang="en"> <h3>Blood thinners for the long‐term treatment of blood clots in people with cancer</h3> <p><b>Background</b><br/>People with cancer are at an increased risk of developing blood clots and might respond differently to different types of blood thinners (anticoagulants). </p> <p><b>Study characteristics</b><br/>We searched scientific databases for clinical trials looking at the effects of long‐term treatment with different blood thinners on blood clot recurrence in people with cancer with a confirmed diagnosis of deep venous thrombosis (a blood clot in the limbs) or pulmonary embolism (a blood clot in the lungs). We included trials with any type of cancer, and irrespective of the type of cancer treatment. The trials looked at survival, recurrent blood clot, bleeding and blood platelet levels (which are involved in blood clotting). The evidence was current to May 2021. </p> <p><b>Key results</b><br/>We found 18trials enrollingparticipants with cancer and blood clots. The studies found that low molecular weight heparins (LMWHs; a type of blood thinner that is injected into a vein) were superior to vitamin K antagonists (VKAs; a type of blood thinner taken by mouth (oral)) in reducing the recurrence of blood clots. The available data did not provide a clear answer about the effects of these drugs on death and the side effect of bleeding. The studies also found that direct oral anticoagulants (DOACs; another type of blood thinner taken by mouth) might decrease the recurrence of blood clots compared to LMWH while increasing the risk of bleeding. There was no clear answer when comparing DOACs (a newer type of oral blood thinner) and VKAs (an older type of oral blood thinner) for death, blood clot recurrence and bleeding. </p> <p><b>Reliability of the evidence</b><br/>When comparing LMWHs to VKAs, we judged the certainty of the evidence to be moderate for recurrent blood clots, death at one year and major bleeding, and low for minor bleeding. </p> <p>When comparing DOACs to VKAs, we judged the certainty of the evidence to be low for death, recurrent blood clots and bleeding complications. </p> <p>Editorial note: this is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.<br/>  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006650-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006650-sec-0099"></div> <h3 class="title" id="CD006650-sec-0100">Implications for practice</h3> <section id="CD006650-sec-0100"> <p>The decision for a person with cancer and venous thromboembolism (VTE) to start long‐term low molecular weight heparin (LMWHs) treatment or oral anticoagulation treatment should balance the benefits and harms and integrate people's values and preferences for outcomes and management options (<a href="./references#CD006650-bbs2-0086" title="HaynesRB , DevereauxPJ , GuyattGH . Clinical expertise in the era of evidence-based medicine and patient choice. Vox Sanguinis2002;83 Suppl 1:383-6.">Haynes 2002</a>). While DOACs compared to LMWHs may show a likely reduction in VTE recurrence, it may show an increase in major bleeding. </p> </section> <h3 class="title" id="CD006650-sec-0101">Implications for research</h3> <section id="CD006650-sec-0101"> <p>There is a need for research assessing patients' values and preferences regarding long‐term anticoagulant agents for treating VTE. Researchers should consider making the raw data from randomized controlled trials (RCTs) available for individual participant data meta‐analysis. Further RCTs including subgroups of people with cancer should report separate results for these subgroups. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006650-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006650-sec-0008"></div> <div class="table" id="CD006650-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low molecular weight heparin secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low molecular weight heparin secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in patients with cancer with venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> People with cancer with venous thromboembolism<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> LMWH secondary prophylaxis<br/><b>Comparison:</b> VKA secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with VKA secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with LMWH secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.88 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>374 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 fewer per 1,000<br/>(45 fewer to 45 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (time‐to‐event)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1243<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.74 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>374 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1,000<br/>(81 fewer to 56 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.44 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 fewer per 1,000<br/>(69 fewer to 25 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism (time‐to‐event)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1243<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.49<br/>(0.31 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 fewer per 1,000<br/>(84 fewer to 26 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/>(0.55 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1,000<br/>(19 fewer to 48 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.47 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 fewer per 1,000<br/>(92 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thrombocytopenia (main analysis‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>138<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.52 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1,000<br/>(122 fewer to 175 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to serious risk of bias (allocation concealment unclear in one study, lack of blinding of participants and personnel in all the four studies, high risk of incomplete outcome data in one study, and high risk of selective reporting in one study). </p> <p><sup>2</sup> Downgraded by one level due to serious imprecision. Confidence interval includes suggests both potential harm and potential benefit. </p> <p><sup>3</sup> Some concern with lack of blinding of patients and personnel. </p> <p><sup>4</sup> Some concern with inconsistency. I2= 46% </p> <p><sup>5</sup> Downgraded by one level due to serious inconsistency (I2= 78%) </p> <p><sup>6</sup> Downgraded by two levels due to very serious imprecision. Confidence interval includes suggests both potential harm and potential benefit. Low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006650-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Direct oral anticoagulant secondary prophylaxis compared to Vitamin K antagonist secondary prophylaxis in patients with active cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Direct oral anticoagulant secondary prophylaxis compared to Vitamin K antagonist secondary prophylaxis in patients with active cancer with venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> patients with active cancer with venous thromboembolism<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> DOAC secondary prophylaxis<br/><b>Comparison:</b> VKA secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Vitamin K antagonist (VKA) secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Direct oral anticoagulant (DOAC) secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1060<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.72 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 fewer per 1,000<br/>(48 fewer to 39 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1050<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.34 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1,000<br/>(32 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1055<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/>(0.39 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1,000<br/>(23 fewer to 20 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1055<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.57 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 fewer per 1,000<br/>(55 fewer to 29 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health related quality of life<br/>follow up: range 3 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8485<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Prins 2014 (EINSTEIN DVT‐PE; n=8485 ): "in the general population of the EINSTEIN studies, patient‐reported satisfaction and quality of life was better in the rivaroxaban‐treated patients than in the group treated with enoxaparin and vitamin K antagonist, although we have not yet examined whether this is the same in patients with active cancer. Hence, it can be expected that quality of life will also be improved with rivaroxaban compared with long‐term injected low molecular‐weight heparin." The tool used was validated measure of treatment satisfaction – the Anti‐Clot Treatment Scale (ACTS)) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Some concern with indirectness (study by Schulman et al (RECOVER I‐II) included patients with a diagnosis of cancer within five years before enrollment), however the weight of these studies was low and heterogeneity was very low. </p> <p><sup>2</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit and potential harm. </p> <p><sup>3</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit and potential no effect. Low number of events. </p> <p><sup>4</sup> Downgraded by one level for serious indirectness. The study by Prins and colleagues (Prins 2014 ( EINSTEIN n=8485)) reports health related quality of life for the whole study population, without providing data for the cancer subgroup </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006650-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Direct oral anticoagulant secondary prophylaxis compared to Low molecular weight heparin secondary prophylaxis in patients with cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Direct oral anticoagulant secondary prophylaxis compared to Low molecular weight heparin secondary prophylaxis in patients with cancer with venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with cancer with venous thromboembolism<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> DOAC secondary prophylaxis<br/><b>Comparison:</b> LMWH secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Low molecular weight heparin (LMWH) secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Direct oral anticoagulant (DOAC) secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2854<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.83 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1,000<br/>(42 fewer to 35 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2854<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.45 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 fewer per 1,000<br/>(48 fewer to 10 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2994<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/>(0.83 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1,000<br/>(6 fewer to 25 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/>(0.62 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 more per 1,000<br/>(8 fewer to 23 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major upper GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/>(0.51 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1,000<br/>(5 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major lower GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(0.43 to 2.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more per 1,000<br/>(5 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major non‐GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/>(0.42 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1,000<br/>(11 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2854<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.58<br/>(1.15 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 more per 1,000<br/>(10 more to 78 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>6 7 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/>(0.41 to 4.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1,000<br/>(15 fewer to 92 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor upper GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>6 7 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/>(0.04 to 25.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1,000<br/>(10 fewer to 267 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor lower GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54<br/>(0.72 to 3.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 more per 1,000<br/>(4 fewer to 33 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor non‐GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>7 10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.37<br/>(1.44 to 3.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 more per 1,000<br/>(14 more to 89 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to serious risk of bias. Allocation concealment was not reported in one study, lack of blinding of patients and personnel in all studies, and high risk of bias related to incomplete outcome data. </p> <p><sup>2</sup> Downgraded by one level due to serious imprecision. Confidence interval suggests both potential benefit and potential harm. </p> <p><sup>3</sup> Downgraded by one level due to serious imprecision. Confidence interval suggests both potential benefit and potential no effect. </p> <p><sup>4</sup> Downgraded by one level due to serious imprecision. Confidence interval suggests both potential harm and potential no effect. </p> <p><sup>5</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential harm and potential no effect. Low number of events. </p> <p><sup>6</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential harm and potential benefit. Low number of events. </p> <p><sup>7</sup> Some concern with risk of bias. Lack of blinding of patients and personnel in both studies. </p> <p><sup>8</sup> Downgraded by one level due to serious inconsistency (unexplained heterogeneity I2=64%) and due to some concern with risk of bias. </p> <p><sup>9</sup> Downgraded by two levels due to very serious inconsistency (unexplained heterogeneity I2=74%.) and due to some concern with risk of bias. </p> <p><sup>10</sup> Downgraded by one level due to serious imprecision. Low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006650-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Idraparinux secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Idraparinux secondary prophylaxis compared to VKA secondary prophylaxis in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population</b>: people with cancer with VTE receiving secondary prophylaxis </p> <p><b>Setting</b>: outpatient </p> <p><b>Intervention</b>: idraparinux prophylaxis </p> <p><b>Control</b>: VKA prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with VKA secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with idraparinux secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>284<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b><br/>(0.78 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 more per 1000<br/>(62 fewer to 167 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>270<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.46</b><br/>(0.16 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 fewer per 1000<br/>(65 fewer to 25 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>270<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b><br/>(0.35 to 3.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(25 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI) </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>VKA:</b> vitamin K antagonist; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious imprecision, 95% CI was consistent with the possibility for important benefit (62 per 1000 absolute reduction) and possibility of important harm (167 per 1000 absolute increase), included 85 events. </p> <p><sup>b</sup>Downgraded two level due to very serious imprecision, 95% CI was consistent with the possibility of important benefit (65 fewer per 1000) and possibility of important harm (25 more per 1000); included 15 events. </p> <p><sup>c</sup>Downgraded two levels due to very serious imprecision, 95% CI was consistent with the possibility for important benefit (25 per 1000 absolute reduction) and possibility of important harm (98 per 1000 absolute increase), included 11 events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006650-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006650-sec-0009"></div> <p>Please refer to the glossary for the definitions of technical terms (<a href="#CD006650-tbl-0005">Table 1</a>). </p> <div class="table" id="CD006650-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A therapy given in addition to the primary treatment to decrease the risk of the cancer recurrence or to assist in the cure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of hindering the clotting of blood especially by treatment with an anticoagulant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antithrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Used against or tending to prevent thrombosis (clotting)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct oral anticoagulants (DOAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also known as NOACs are anticoagulant medications that require less monitoring compared to the traditional anticoagulants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (as swelling and pain) and that is potentially life‐threatening if dislodgment of the thrombus results in pulmonary embolism. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fondaparinux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An anticoagulant medication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hemostatic system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The system that shortens the clotting time of blood and stops bleeding.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. 2 forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impedance plethysmography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kappa statistic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A measure of degree of nonrandom agreement between observers, measurements of a specific categorical variable, or both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The spread of a cancer cells from the initial or primary site of disease to another part of the body. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parenteral nutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The practice of feeding a person intravenously, circumventing the gastrointestinal tract. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Embolism of a pulmonary artery or one of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing, chest pain, fainting, rapid heart rate, cyanosis, shock and sometimes death. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent decrease in the number of blood platelets that is often associated with hemorrhagic conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The formation or presence of a blood clot within a blood vessel.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulant medications. Warfarin is a vitamin K antagonist.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An anticoagulant medication that is a vitamin K antagonist that is used for anticoagulation.</p> </td> </tr> </tbody> </table> </div> <section id="CD006650-sec-0010"> <h3 class="title" id="CD006650-sec-0010">Description of the condition</h3> <p>Cancer is associated with an increased risk of venous thromboembolism (VTE) of four‐ to six‐fold (<a href="./references#CD006650-bbs2-0087" title="HeitJA , SilversteinMD , MohrDN , PettersonTM , O'FallonWM , MeltonLJ . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine2000;160(6):809-15.">Heit 2000</a>). Cancer‐related interventions such as chemotherapy, hormonal therapy and indwelling central venous catheters also increase the risk of VTE (<a href="./references#CD006650-bbs2-0087" title="HeitJA , SilversteinMD , MohrDN , PettersonTM , O'FallonWM , MeltonLJ . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine2000;160(6):809-15.">Heit 2000</a>). Similarly, people undergoing surgery for cancer have a higher risk of VTE than people undergoing surgery for diseases other than cancer (<a href="./references#CD006650-bbs2-0083" title="GallusAS . Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thrombosis and Haemostasis1997;78(1):126-32.">Gallus 1997</a>; <a href="./references#CD006650-bbs2-0093" title='KakkarVV , HoweCT , NicolaidesAN , RenneyJT , ClarkeMB . Deep vein thrombosis of the leg. Is there a "high risk" group?American Journal of Surgery1970;120(4):527-30.'>Kakkar 1970</a>). Furthermore, people with cancer and VTE have a higher risk of death than people with cancer alone or with VTE alone (<a href="./references#CD006650-bbs2-0095" title="LevitanN , DowlatiA , RemickSC , TahsildarHI , SivinskiLD , BeythR , et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine1999;78(5):285-91.">Levitan 1999</a>; <a href="./references#CD006650-bbs2-0103" title="SorensenHT , MellemkjaerL , OlsenJH , BaronJA . Prognosis of cancers associated with venous thromboembolism. New England Journal of Medicine2000;343(25):1846-50.">Sorensen 2000</a>). </p> <p>People with cancer also have different benefits and risks from anticoagulant treatment than people without cancer. For instance, during oral anticoagulation therapy for VTE, people with cancer, compared with people without cancer, have a higher incidence of recurrent VTE (27.1 events per 100 participant‐years with cancer versus 9.0 events per 100 participant‐years without cancer; P = 0.003) and of major bleeding (13.3 events per 100 participant‐years with cancer versus 2.2 events per 100 participant‐years without cancer; P = 0.002) (<a href="./references#CD006650-bbs2-0090" title="HuttenBA , PrinsMH , GentM , GinsbergJ , TijssenJG , BullerHR . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. Journal of Clinical Oncology2000;18(17):3078-83.">Hutten 2000</a>). </p> </section> <section id="CD006650-sec-0011"> <h3 class="title" id="CD006650-sec-0011">Description of the intervention</h3> <p>Low molecular weight heparins (LMWHs) do not have intrinsic anticoagulant activity but potentiate the activity of antithrombin III in inhibiting activated coagulation factors. These agents constitute indirect anticoagulants as their activity is mediated by plasma cofactors. LMWHs are not absorbed orally and must be administered parenterally by subcutaneous injections (<a href="./references#CD006650-bbs2-0089" title="HirshJ . Low molecular weight heparin. Thrombosis and Haemostasis1993;70(1):204-7.">Hirsh 1993</a>). </p> <p>Direct oral anticoagulant (DOACs) are a new generation of medications with a rapid onset of action that allows a fixed‐dose treatment, and may simplify treatment of VTE by eliminating the need for an initial parenteral anticoagulation (<a href="./references#CD006650-bbs2-0071" title="AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808.">Agnelli 2013</a>). </p> <p>Vitamin K antagonists (VKAs) have been the mainstay of oral anticoagulant therapy since the 1950s. Well‐designed clinical trials have shown the effectiveness of VKAs for the primary and secondary prevention of several venous and arterial thrombotic diseases (<a href="./references#CD006650-bbs2-0076" title="AnsellJ , HirshJ , HylekE , JacobsonA , CrowtherM , PalaretiG . Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008;133(Suppl 6):160S-98S.">Ansell 2008</a>). </p> </section> <section id="CD006650-sec-0012"> <h3 class="title" id="CD006650-sec-0012">How the intervention might work</h3> <p>Several systematic reviews have compared LMWHs, DOACs and VKAs in the long‐term treatment of VTE, but in populations not representative of people with cancer (<a href="./references#CD006650-bbs2-0078" title="ContiS , GuerciniF , IorioA . Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiology of Haemostasis &amp; Thrombosis2003;33(4):197-201.">Conti 2003</a>; Iorio 2003; <a href="./references#CD006650-bbs2-0107" title="van derHeijdenJF , HuttenBA , BüllerHR , PrinsMH . Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD002001. [DOI: 10.1002/14651858.CD002001]">van der Heijden 2007</a>). The review by van der Heijden and colleagues did not complete a preplanned subgroup analysis in people with cancer as the required data were not specifically reported (<a href="./references#CD006650-bbs2-0107" title="van derHeijdenJF , HuttenBA , BüllerHR , PrinsMH . Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD002001. [DOI: 10.1002/14651858.CD002001]">van der Heijden 2007</a>). The review by Conti and colleagues did not conduct a meta‐analysis in the subgroup of people with cancer (<a href="./references#CD006650-bbs2-0078" title="ContiS , GuerciniF , IorioA . Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiology of Haemostasis &amp; Thrombosis2003;33(4):197-201.">Conti 2003</a>). In the review by Iorio and colleagues, one meta‐analysis in the subgroup of people with cancer found no significant difference in mortality (odds ratio 1.13, 95% confidence interval (CI) 0.54 to 2.38). </p> </section> <section id="CD006650-sec-0013"> <h3 class="title" id="CD006650-sec-0013">Why it is important to do this review</h3> <p>We initially conducted this and other reviews on this topic and their updates to directly and better inform clinical practice guidelines. This is fourth versions of this review (previous version published respectively in 2007, 2011, 2016 and cite them). The last major update of this Cochrane systematic review, published in 2018, identified 16 trials. It concluded that the LMWHs compared to VKAs probably produces an important reduction in VTE, and DOACs compared to LMWH may likely reduce VTE but may increase risk of major bleeding (<a href="./references#CD006650-bbs2-0114" title="KahaleLA , HakoumMB, TsolakianIG , MatarCF , TerrenatoI , SperatiF , BarbaM , YosuicoVED , SchünemannH , AklEA . Anticoagulation for the long-termtreatment of venous thromboembolism in people with cancer. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD006650. [DOI: 10.1002/14651858.CD006650.pub5]">Kahale 2018</a>). Since 2018, we have identified three new eligible trials and one full‐text publication of a previously identified abstract) addressing this question. </p> <p><b>Living review approach:</b> since the publication of the 2018 update of the review, we are maintaining it as a living systematic review. This means we will be continually running the searches and rapidly incorporating any newly identified evidence (for more information about the living systematic review approach, see <a href="./appendices#CD006650-sec-0105">Appendix 1</a>). We believe a living systematic review approach is appropriate for this review for four reasons. First, the review addresses an important topic for clinical practice; people with cancer being treated for VTE have a relatively high rate of VTE recurrence. For instance, during oral anticoagulation therapy for VTE, people with cancer, compared with people without cancer, have a higher incidence of recurrent VTE (27.1 events per 100 participant‐years with cancer versus 9.0 events per 100 participant‐years without cancer; P = 0.003) (<a href="./references#CD006650-bbs2-0090" title="HuttenBA , PrinsMH , GentM , GinsbergJ , TijssenJG , BullerHR . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. Journal of Clinical Oncology2000;18(17):3078-83.">Hutten 2000</a>). Second, there remains uncertainty in the existing evidence in relation to the outcomes of mortality and bleeding. Third, we are aware of five ongoing eligible trials that will be important to incorporate in a timely manner. Fourth, this living systematic review may be used as part of a living guideline project  (<a href="./references#CD006650-bbs2-0074" title="AklEA , MeerpohlJJ , ElliottJH , KahaleLA , Schünemann HJ on behalf of the Living Systematic Review Network. Living systematic reviews: 4. living guideline recommendations. Journal of Clinical Epidemiology2017;91:47-53.">Akl 2017</a>).  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006650-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006650-sec-0014"></div> <p> <ul id="CD006650-list-0001"> <li> <p>To compare the efficacy and safety of anthithrombotics including low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs),  vitamin K antagonists (VKAs), and Idraparinuxfor the long‐term treatment of venous thromboembolism (VTE) in people with cancer. </p> </li> <li> <p>To maintain this review as a living systematic review by continually running the searches and incorporating newly identified studies. </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006650-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006650-sec-0015"></div> <section id="CD006650-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006650-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs).</p> </section> <section id="CD006650-sec-0018"> <h4 class="title">Types of participants</h4> <p>People with active cancer with a confirmed diagnosis of VTE (deep venous thrombosis (DVT) or pulmonary embolism (PE)). Participants could have been of any age group (including children), with either solid or hematologic cancer, at any cancer stage and irrespective of the type of cancer therapy. VTE should have been diagnosed using an objective diagnostic test. </p> <p>Cancer should have been diagnosed by the time of inclusion in the study.</p> <p>We included studies with at least 75% of participants with a cancer status being active (i.e., we excluded studies with more than 25% of participants with non‐active cancer). If between 25% and 75% of the population had active cancer and outcome data for this subgroup of people were not reported, we excluded such studies from the main analysis and included them in the sensitivity analysis. </p> </section> <section id="CD006650-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Intervention arms consisted of long‐term treatment with antithrombtics including (beyond 3 months of initial treatment) : </p> <p> <ul id="CD006650-list-0002"> <li> <p>LMWHs;</p> </li> <li> <p>DOACs;</p> </li> <li> <p>VKAs;</p> </li> <li> <p>Idraparinux</p> </li> </ul> </p> <p>We included any comparison of the three management options listed above (LMWHs versus VKAs, DOACs versus VKAs, DOACs versus LMWHs; idra). Cointerventions, if any, should have been balanced across the groups compared. </p> </section> <section id="CD006650-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD006650-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006650-list-0003"> <li> <p>All‐cause mortality.</p> </li> </ul> </p> </section> <section id="CD006650-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006650-list-0004"> <li> <p>Symptomatic recurrent DVT: DVT events suspected clinically, and confirmed using an objective diagnostic test such as: venography, <sup>125</sup>I‐fibrinogen‐uptake test, impedance plethysmography or compression ultrasound. </p> </li> <li> <p>Symptomatic recurrent PE: PE events suspected clinically, and confirmed using an objective diagnostic test such as: pulmonary ventilation/perfusion scans, computed tomography, pulmonary angiography or autopsy. </p> </li> <li> <p>Symptomatic VTE:</p> </li> <li> <p>Major bleeding: we accepted the authors' definitions of major bleeding.</p> </li> <li> <p>Minor bleeding: we accepted the authors' definitions of minor bleeding.</p> </li> <li> <p>Thrombocytopenia: we accepted the authors' definitions of thrombocytopenia.</p> </li> <li> <p>Health‐related quality of life measured using a validated tool.</p> </li> <li> <p>Postphlebetic syndrome.</p> </li> </ul> </p> </section> </section> </section> <section id="CD006650-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006650-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The search was part of a comprehensive search for studies of anticoagulation in people with cancer. We conducted a comprehensive search on 14 May 2021, following the a major search in February 2016. We electronically searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (starting 1946, via Ovid), and Embase (starting 1980, via Ovid). We used no language restrictions.The search strategies combined terms for anticoagulants, terms for cancer and a search filter for RCTs. We used no language restrictions. The search strategy was revised by an information specialist (JP). We list the full search strategiy for each of the electronic databases in <a href="./appendices#CD006650-sec-0109">Appendix 2</a>. </p> <p><b>Living systematic review approach:</b> We will be updating the searches using auto‐alerts on a monthly basis. We will publish an update every six months to incorporate any new identified evidence. This update of the systematic review is based on the findings of a literature search conducted on 14 May 2021. We will review search methods and strategies approximately yearly, to ensure they reflect any terminology changes in the topic area, or in the databases. </p> </section> <section id="CD006650-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched the conference proceedings of the American Society of Clinical Oncology (ASCO, starting with its first volume, 1982 up to May 2021) and of the American Society of Hematology (ASH, starting with its 2003 issue up to May 2021). We also searched <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and <a href="http://www.who.int/ictrp/search/en/" target="_blank">World Health Organization (WHO) International Clinical Trials Registry Platform</a> for ongoing studies. We reviewed the reference lists of papers included in this review and of other relevant systematic reviews.. In addition, we contacted experts in the field for information about unpublished work and ongoing trials. </p> <p><b>Living review approach:</b> we will search  the conference proceedings of ASCO and ASH soon after their publications and <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and <a href="http://www.who.int/ictrp/search/en/" target="_blank">WHO International Clinical Trials Registry Platform</a>. . We will continue to review the reference lists for any prospectively identified studies specify in differences between protocol </p> </section> </section> <section id="CD006650-sec-0026"> <h3 class="title" id="CD006650-sec-0026">Data collection and analysis</h3> <section id="CD006650-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Four pairs of review authors (LAK, FA, MBK, CFM, VEDY, IT, FS, MB, IGT) independently screened the title and abstract of identified articles for potential eligibility. We retrieved the full text of articles judged potentially eligible by at least one review author. Then, the pairs of authors  independently screened the full‐text article for eligibility using a standardized form piloted on 500 RCTs with explicit inclusion and exclusion criteria (as detailed in the <a href="#CD006650-sec-0016">Criteria for considering studies for this review</a> section) and resolved any disagreements by discussion or by consulting a third review author. </p> <p><b>Living systematic review approach:</b> for the monthly searches, we will immediately screen the new citations retrieved each month. As the first step of monthly screening, we will apply the machine learning classifier (RCT model) available in the Cochrane Register of Studies (<a href="./references#CD006650-bbs2-0079" title="Cochrane Community. CRS (Cochrane Register of Studies). community.cochrane.org/help/tools-and-software/crs-cochrane-register-studies (accessed 9 June 2018).">CSR‐web</a>; <a href="./references#CD006650-bbs2-0109" title="WallaceBC , Noel-StorrA , MarshallIJ , CohenAM , SmalheiserNR , ThomasJ . Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowd sourcing approach. Journal of the American Medical Informatics Association2017;0(0):1-4.">Wallace 2017</a>). The classifier assigns a probability (from 0 to 100) to each citation for being a true RCT. For citations that are assigned a probability score of less than 10, the machine learning classifier currently has a specificity/recall of 99.987% (<a href="./references#CD006650-bbs2-0106" title="ThomasJ , Noel-StorrA , MarshallI , WallaceB , McDonaldS , MavergamesC , GlasziouP , ShemiltI , SynnotA , TurnerT , ElliottJ . Living systematic reviews: 2. Combining human and machine effort. Journal of clinical epidemiology 2017 Nov 1;91:31-7.">Thomas 2017</a>; <a href="./references#CD006650-bbs2-0109" title="WallaceBC , Noel-StorrA , MarshallIJ , CohenAM , SmalheiserNR , ThomasJ . Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowd sourcing approach. Journal of the American Medical Informatics Association2017;0(0):1-4.">Wallace 2017</a>)). For citations assigned a score from 10 to 100, we will screen them in duplicate and independently. Citations that score 9 or less will be screened by Cochrane Crowd (<a href="./references#CD006650-bbs2-0077" title="Cochrane Crowd. Cochrane Crowd. crowd.cochrane.org/index.html (accessed 9 June 2018).">Cochrane Crowd</a>). Any citations that are deemed to be potential RCTs by Cochrane Crowd will be returned to the authors for screening. </p> </section> <section id="CD006650-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Four pairs of review authors (LAK, FA, IT, IGT) independently extracted the data from each study and resolved any disagreements by discussion or by consulting a third review author. We aimed to collect data related to the following. </p> <section id="CD006650-sec-0029"> <h5 class="title">Participants</h5> <p> <ul id="CD006650-list-0005"> <li> <p>Number of participants randomized to each study arm.</p> </li> <li> <p>Number of participants followed up in each study arm.</p> </li> <li> <p>Number of participants who discontinued treatment in each arm.</p> </li> <li> <p>Population characteristics (e.g., age, gender, co morbidities).</p> </li> <li> <p>Type of cancer (site,histology).</p> </li> <li> <p>Stage of cancer.</p> </li> </ul> </p> <p>We defined active cancer as (1) non‐squamous cell or basal cell invasive cancer diagnosed within 6 months before enrollment, (2) cancer treated within the previous 6 months, (3) recurrent or metastatic cancer, or (4) reported as active cancer during the study. </p> <p>We extracted outcome data for people with active cancer. If the study included both people with active cancer and people with non‐active cancer, we sought outcome data for the subgroup of people with active cancer. </p> </section> <section id="CD006650-sec-0030"> <h5 class="title">Interventions</h5> <p> <ul id="CD006650-list-0006"> <li> <p>Type of anticoagulant.(LMWH, VKA, or DOAC)</p> </li> <li> <p>Dosage or intensity of anticoagulation</p> </li> <li> <p>Duration of long‐term and initial treatment</p> </li> <li> <p>Cointerventions including chemotherapy, target therapy, immunotherapy, radiation therapy, or a combination of these (type and duration). </p> </li> </ul> </p> </section> <section id="CD006650-sec-0031"> <h5 class="title">Outcomes</h5> <p>We extracted both time‐to‐event data (for the mortality and recurrence of VTE outcomes) and dichotomous data (for all outcomes). </p> <p>For time‐to‐event data, we abstracted the log (hazard ratio (HR)) and its variance from trial reports; if these were not reported, we digitized the published Kaplan‐Meier survival curves and estimated the log (HR) and its variance using the method of Parmar (<a href="./references#CD006650-bbs2-0097" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>). We also noted the minimum and maximum duration of follow‐up, which were required to make these estimates. We performed these calculations in <a href="./references#CD006650-bbs2-0104" title="Stata Statistical Software: Release 9. StataCorp. College Station, TX: StataCorp LP, 2005.">Stata 9</a> using a specially written program, which yielded the reported log (HR) and variance when used on the data presented in Table V of <a href="./references#CD006650-bbs2-0097" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>. </p> <p>For dichotomous data, we collected for each outcome and per arm number of events, number of participants randomized, and number of participants with incomplete data. </p> <p>For the outcome major bleeding, we extracted events among people with gastrointestinal (GI) tract cancer and people without GI tract cancer. We further extracted major GI bleeding, major upper GI bleeding, major lower GI bleeding, and major non‐GI bleeding. </p> <p>We attempted to contact study authors for incompletely reported data. We decided a priori to consider abstracts in the main analysis only if authors supplied us with full reports of their methods and results, otherwise we included abstracts in the sensitivity analysis </p> <p>None of the outcomes of interest were continuous variables.</p> </section> <section id="CD006650-sec-0032"> <h5 class="title">Other</h5> <p>We extracted from each included trial any information on the following:</p> <p> <ul id="CD006650-list-0007"> <li> <p>Ethical approval;</p> </li> <li> <p>Source of funding;</p> </li> <li> <p>Conflict of interest.</p> </li> </ul> </p> </section> </section> <section id="CD006650-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias at the study level using Cochrane's 'Risk of bias' tool (<a href="./references#CD006650-bbs2-0088" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Four pairs of review authors ((LAK, FA, IT, IGT) independently assessed the methodologic quality of each included study and resolved any disagreements by discussion. Methodologic criteria included:<br/>  </p> <p> <ul id="CD006650-list-0008"> <li> <p>Adequate  sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding of participants and personnel;</p> </li> <li> <p>Blinding of outcome assessment;</p> </li> <li> <p>Incomplete outcome data ;</p> </li> <li> <p>Selective outcome reporting;</p> </li> <li> <p>Other bias (e.g., whether the study was stopped early for benefit).</p> </li> </ul> </p> <p>See the <a href="#CD006650-sec-0036">Dealing with missing data</a> section about assessing risk of bias associated with participants with missing data per outcome and across studies. </p> <p>We attempted to contact the authors for any study domain that was unclear. We re‐evaluated our judgment when authors provided clarification. </p> </section> <section id="CD006650-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We analyzed hazard ratio (HR) for time‐to‐event data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI). None of the outcomes of interest was meta‐analyzed as a continuous variable. </p> </section> <section id="CD006650-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant.</p> </section> <section id="CD006650-sec-0036"> <h4 class="title">Dealing with missing data</h4> <section id="CD006650-sec-0037"> <h5 class="title">Identifying participants with missing data</h5> <p>It was not clear whether certain categories of participants (e.g. those described as 'withdrew consent' or 'experienced adverse events') were actually followed up by the trial authors (versus had missing data) (<a href="./references#CD006650-bbs2-0073" title="AklEA , KahaleLA , EbrahimS , Alonso-CoelloP , SchünemannHJ , GuyattGH . Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers. Journal of Clinical Epidemiology2016;76:147-54.">Akl 2016</a>). To identify participants with missing data, we followed the guidance suggested by Kahale et al (<a href="./references#CD006650-bbs2-0091" title="KahaleLA , GuyattGH , AgoritsasT , BrielM , BusseJW , Carrasco-LabraA , KhamisAM , ZhangY , HooftL , ScholtenRJ , AklEA . A guidance was developed to identify participants with missing outcome data in randomized controlled trials. Journal of clinical epidemiology2019;115:55-63.">Kahale 2019</a>) : </p> <p> <ul id="CD006650-list-0009"> <li> <p>Definitely not missing data: (1) participants explicitly reported as followed‐up; (2) participants who died during the trial; (3) participants belonging to centres that were excluded. </p> </li> <li> <p>Definitely missing data: (1) participants explicitly reported as not followed up; (2) participants with unclear follow‐up status and (a) excluded from the denominator of the analysis (i.e., complete case analysis); or (b) included in the denominator of the analysis and their outcomes were explicitly stated to be imputed. However, we did not treat them as missing data unless it is possible to obtain the number of observed/actual events (i.e., excluding imputed events) to avoid double counting. </p> </li> <li> <p>Potentially missing data: Participants with unclear follow‐up status (e.g., included in the denominator of the analysis and their outcomes were not explicitly stated to be imputed). </p> </li> </ul> </p> </section> <section id="CD006650-sec-0038"> <h5 class="title">Dealing with participants with missing data in the primary meta‐analysis</h5> <p>In the primary meta‐analysis, we used a complete‐case analysis approach, i.e., we excluded participants considered to have missing data (<a href="./references#CD006650-bbs2-0085" title="GuyattGH , EbrahimS , Alonso-CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017;87:14-22.">Guyatt 2017</a>; <a href="./references#CD006650-bbs2-0092" title="KahaleLA , KhamisAM , DiabB , ChangY , LopesLC , AgarwalA , LiL , MustafaRA , KoujanianS , WaziryR , Busse JW. Potential impact of missing outcome data on treatment effects in systematic reviews: imputation study.. BMJ2020;370:m2898.">Kahale 2020</a>). </p> <p>For categorical data, we used the following calculations for each study arm:</p> <p> <ul id="CD006650-list-0010"> <li> <p>denominator: (number of participants randomized) – (number of participants definitely with missing data); </p> </li> <li> <p>numerator: number of participants with observed events (i.e. participants who experienced at least one event for the outcome of interest during their available follow‐up time). </p> </li> </ul> </p> </section> <section id="CD006650-sec-0039"> <h5 class="title">Assessing the risk of bias associated with participants with missing data</h5> <p>When the primary meta‐analysis of a specific outcome found a statistically significant effect, we conducted sensitivity meta‐analyses to assess the risk of bias associated with missing outcome data. Those sensitivity meta‐analyses used a priori plausible assumptions about the outcomes of participants considered to have missing data. The assumptions we used in the sensitivity meta‐analyses were increasingly stringent in order to challenge the statistical significance of the results of the primary analysis progressively (<a href="./references#CD006650-bbs2-0072" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PloS One2013;8(2):e57132.">Akl 2013</a>; <a href="./references#CD006650-bbs2-0092" title="KahaleLA , KhamisAM , DiabB , ChangY , LopesLC , AgarwalA , LiL , MustafaRA , KoujanianS , WaziryR , Busse JW. Potential impact of missing outcome data on treatment effects in systematic reviews: imputation study.. BMJ2020;370:m2898.">Kahale 2020</a>). </p> <p>For categorical data and for an RR showing a reduction in effect (RR &lt; 1), we used the following increasingly stringent but plausible assumptions: </p> <p> <ul id="CD006650-list-0011"> <li> <p>For the control arm, relative incidence (RI) among those with missing data (lost to follow‐up (LTFU)) compared with those with available data (followed up, FU) in the same arm (RI<sub>LTFU/FU</sub>) = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 1.5; </p> </li> <li> <p>For the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 2; </p> </li> <li> <p>For the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 3; </p> </li> <li> <p>For the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 5. </p> </li> </ul> </p> <p>For RR showing an increase in effect (RR &gt; 1), we switched the above assumptions between the control and interventions arms (i.e. used RI<sub>LTFU/FU</sub> = 1 for the intervention arm). </p> <p>Specifically, we used the following calculations for each study arm:</p> <p> <ul id="CD006650-list-0012"> <li> <p>denominator: (number of participants randomized)</p> </li> <li> <p>numerator: (number of participants with observed events) + (number of participants definitely with missing data with assumed events). </p> </li> </ul> </p> <p>Assumed events are calculated by applying the a priori plausible assumptions to the participants definitely with missing data. </p> </section> </section> <section id="CD006650-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between trials by visual inspection of forest plots, estimation of the percentage heterogeneity between trials that could not be ascribed to sampling variation (I<sup>2</sup> test; <a href="./references#CD006650-bbs2-0088" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), and by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD006650-bbs2-0080" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London: BMJ Publication Group, 2001.">Deeks 2001</a>). If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this (see section on <a href="#CD006650-sec-0043">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD006650-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to create funnel plots for outcomes including 10 or more trials .</p> </section> <section id="CD006650-sec-0042"> <h4 class="title">Data synthesis</h4> <p>For time‐to‐event data, we pooled the log(HRs) using a random‐effects model (<a href="./references#CD006650-bbs2-0081" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">DerSimonian 1986</a>), and the generic inverse variance facility of Review Manager 5.4.1 (<a href="./references#CD006650-bbs2-0099" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). For dichotomous data, we calculated the RR separately for each study. When analyzing data related to participants who were reported as non‐compliant, we attempted to adhere to the principles of intention‐to‐treat (ITT) analysis. We approached the issue of non‐compliance independently from that of missing data (<a href="./references#CD006650-bbs2-0075" title="AlshurafaM , BrielM , AklEA , HainesT , MoayyediP , GentlesSJ , et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PloS One2012;7(11):e49163.">Alshurafa 2012</a>). We then pooled the results of the different studies using a random‐effects model. We assessed the certainty evidence at the outcome level using the GRADE approach for each of the following comparisons and outcomes (<a href="./references#CD006650-bbs2-0084" title="SchünemannH , BrożekJ , GuyattG , OxmanA . GRADE Handbook. gdt.guidelinedevelopment.org/app/handbook/handbook.html Updated October 2013.">GRADE Handbook</a>): </p> <p> <ul id="CD006650-list-0013"> <li> <p>LMWH versus VKA</p> </li> <li> <p>DOAC versus VKA</p> </li> <li> <p>DOAC versus LMWH</p> </li> <li> <p>Idraparinux versus VKA</p> </li> </ul> </p> <p>We included in the primary analysis all studies that provided outcome data for particpants with active cancer, and in the sensitivity analysis all studies that included between 25% and 75% of their study sample participants with active cancer and did not provide outcome data for this subgroup of people. </p> <p><b>Living systematic review approach:</b> whenever new evidence (studies, data or information) that meets the review inclusion criteria is identified, we will immediately assess risk of bias and extract the data and incorporate it in the synthesis, as appropriate. We will not adjust the meta‐analyses to account for multiple testing given the methods related to frequent updating of meta‐analyses are under development (<a href="./references#CD006650-bbs2-0102" title="SimmondsME , SalantiG , HigginsJE , McKenzieJ , Elliott JE on behalf of the Living Systematic Review Network. Living Systematic Reviews: 3. Statistical methods for updating meta-analyses. Journal of Clinical Epidemiology2017;91:38-46.">Simmonds 2017</a>). </p> </section> <section id="CD006650-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Since anticoagulants might perfom differently in participants with GI tract cancer (CITATION), we planned to do a subgroup analysis for the outcome major bleeding among participants with GI tract cancer and those without GI tract cancer. We included studies that </p> <p> <ul id="CD006650-list-0014"> <li> <p>Recruited only patients with GI tract cancer and studies that recruited only participants with non‐GI tract cancer; </p> </li> <li> <p>Recruited both GI and non‐GI tract cancer if they provided outcome data for subgroups of participants with GI tract cancer and data for subgroups of participants with non‐GI tract cancer; </p> </li> <li> <p>Recruited both GI tract and non‐GI tract cancer but did not provide subgroup data only if more than 75% of participants had GI tract cancer or more than 75% of participants had non‐GI tract cancer. </p> </li> </ul> </p> <p>If the proportion of participants with GI tract cancer ranged between 25% and 75% and outcome data for this subgroup was not provided, we did not include such a study in the subgroup analysis. </p> <p>For this subgroup analysis, we did not conduct complete case analysis for the primary analysis as noted under Dealing with missing data section. Instead we used the denominator reported in the analysis of each study report in order to balance numbers of participants with GI tract cancer and those without GI tract cancer. </p> <p> </p> </section> <section id="CD006650-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p> </p> <p>We decided a priori to consider abstracts and completed studies published exclusively on <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> in the main analysis only if study authors supplied us with full reports of their methods and results; otherwise abstracts were included only in the sensitivity analysis. </p> <p>As described earlier under Dealing with missing data section, we also planned for sensitivity meta‐analyses to assess the risk of bias associated with missing outcome data when the primary meta‐analysis of a specific outcome found a statistically significant effect. </p> <p>In addition, we planned a sensitivity analysis including studies that included between 25% and 75% of their study sample participants with active cancer and did not provide outcome data for this subgroup of people. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006650-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006650-sec-0045"></div> <section id="CD006650-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD006650-sec-0047"> <h4 class="title">Results of the search</h4> <p><a href="#CD006650-fig-0001">Figure 1</a> shows the study flow diagram. As of May 2021, the search strategy identified 3583 unique citations. The title and abstract screening identified 102 potentially eligible citations. The full‐text screening of the full texts of these 102  citations identified 19eligible RCTs published as full reports (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>; <a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>), and two studies published as abstracts (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). Since the last major update in May 2018, we included the full text of two previously identified ongoing studies (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>, included the full text of a previously previously identified abstract (<a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>, included the full text of a new study (<a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>). We identified five registered but unpublished trials: one terminated (<a href="./references#CD006650-bbs2-0066" title="KleinjanA , Di NisioM , KamphuisenPW , BullerHR , on behalf of the steering committee. Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism – a randomized controlled trial. 5th ICTHIC Abstracts: Poster Sessions / Thrombosis Research2010;125(PO-67):S184. ">Kamphuisen 2010 (Longheva)</a>) and four ongoing (<a href="./references#CD006650-bbs2-0066" title="KleinjanA , Di NisioM , KamphuisenPW , BullerHR , on behalf of the steering committee. Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism – a randomized controlled trial. 5th ICTHIC Abstracts: Poster Sessions / Thrombosis Research2010;125(PO-67):S184. ">Kamphuisen 2010 (Longheva)</a>; <a href="./references#CD006650-bbs2-0067" title="Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. Ongoing study. March 2016. Contact author for more information.">Karatas 2015</a>;  <a href="./references#CD006650-bbs2-0068" title="Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). Ongoing study. September 2016. Contact author for more information.">Meyer 2016 (CASTA‐DIVA)</a>; <a href="./references#CD006650-bbs2-0069" title="A randomized phase II study to compare the safety and efficacy of dalteparin vs. rivaroxaban for cancer-associated venous thromboembolism (PRIORITY). Ongoing study. May 2017. Contact author for more information.">Ryun Park 2017 (PRIORITY)</a>; <a href="./references#CD006650-bbs2-0070" title="Direct oral anticoagulants (DOACs) versus LMWH ± warfarin for VTE in cancer (CANVAS). Ongoing study. December 2016. Contact author for more information.">Schrag 2016 (CANVAS)</a>). . </p> <div class="figure" id="CD006650-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006650-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006650-sec-0048"> <h4 class="title">Included studies</h4> <p>We included 19 RCTs (55 reports) with  participants with cancer for which outcome data were available (see <a href="./references#CD006650-sec-0120" title="">Characteristics of included studies</a> table). </p> <p>Eight RCTs compared LMWHs to VKAs for the long‐term treatment of VTE (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>); only one of these studies used a different initial anticoagulant in the two study arms (LMWH in the LMWH group and UFH in the VKA group) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). Four studies did not explictly specify whether patients had active cancer or did not provide outcome data for subgroups of patients with active cancer (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>). </p> <p>Five RCTs compared DOACs to VKAs (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>). One study did not explictly specify whether patients had active cancer (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). One RCT compared a once‐weekly subcutaneous injection of idraparinux for three or six months versus standard treatment (tinzaparin, enoxaparin or dose‐adjusted intravenous heparin followed by warfarin or acenocoumarol; <a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>).  </p> <p>Five studies compared DOACs to LMWHs (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). We also identified five ongoing studies comparing DOACs to LMWHs (<a href="./references#CD006650-bbs2-0066" title="KleinjanA , Di NisioM , KamphuisenPW , BullerHR , on behalf of the steering committee. Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism – a randomized controlled trial. 5th ICTHIC Abstracts: Poster Sessions / Thrombosis Research2010;125(PO-67):S184. ">Kamphuisen 2010 (Longheva)</a>; <a href="./references#CD006650-bbs2-0067" title="Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. Ongoing study. March 2016. Contact author for more information.">Karatas 2015</a>; <a href="./references#CD006650-bbs2-0068" title="Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). Ongoing study. September 2016. Contact author for more information.">Meyer 2016 (CASTA‐DIVA)</a>; <a href="./references#CD006650-bbs2-0069" title="A randomized phase II study to compare the safety and efficacy of dalteparin vs. rivaroxaban for cancer-associated venous thromboembolism (PRIORITY). Ongoing study. May 2017. Contact author for more information.">Ryun Park 2017 (PRIORITY)</a>; <a href="./references#CD006650-bbs2-0070" title="Direct oral anticoagulants (DOACs) versus LMWH ± warfarin for VTE in cancer (CANVAS). Ongoing study. December 2016. Contact author for more information.">Schrag 2016 (CANVAS)</a>)). </p> <p>Agnelli and colleagues recruited 169 participants with active cancer and VTE, a subgroup in the AMPLIFY trial, and followed them up for six months (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>). Participants were randomized to receive apixaban (10 mg twice daily for seven days followed by 5 mg twice daily) or enoxaparin (1 mg kg twice daily for at least five days) followed by dose‐adjusted warfarin (target international normalized ratio (INR) of 2 to 3). Assessed outcomes were mortality, recurrent VTE and major bleeding. It is of note that 25 participants (13 in the apixaban group and 12 in the enoxaparin/warfarin group) without cancer or a history of cancer at baseline were diagnosed with cancer after treatment assignment.  </p> <p>Agnelli and colleagues recruited and analized 1155 participants with active cancer from 119 centers in 9 European countries, Israel and The U.S.A.(<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>). Participants were randomized to receive apixaban 10 mg twice daily for seven days then 5 mg twice daily for a total of six months or dalteparin 200 IU/kg once daily for the first month and than 150 IU/kg daily for a total of six months. Assessed outcomes were all cause mortality, recurrent VTE, recurrent DVT, PE, major and minor bleeding. Gastrointestinal bleeding was also reported. Participants were followed up for six months. </p> <p>Cesarone and colleagues recruited 199 participants with cancer and DVT (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>). The authors did not report whether the participants had active cancer or not. Participants were randomized to receive enoxaparin 100 Ul/kg twice daily or coumadin (dose adjusted to keep INR close to 3) for three months. Assessed outcomes were mortality and major outcome event in the three‐month period.  </p> <p>Deitcher and colleagues recruited 102 participants with active cancer with acute symptomatic VTE (<a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>). Participants were randomized to receive enoxaparin subcutaneous twice daily (1.0 mg/kg) for five days followed by once daily enoxaparin for 175 days or enoxaparin subcutaneous twice daily (1.0 mg/kg) for five days then warfarin starting day two of enoxaparin for 180 days. Assessed outcomes were mortality, recurrent VTE, and major and minor bleeding. . </p> <p>El Mokadem and colleagues recruited and analyzed 138 participants with active cancer and acute DVT (<a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>). Participants were randomized to receive apixaban 10 mg twice daily for seven days then 5 mg twice daily for a total of six months or enoxaparin 1 mg/kg/sc every 12 h for a total of six months. Assessed outcomes were mortality,recurrence of DVT and PE, major bleeding, and minor bleeding. Participants were followed up for six months. </p> <p>Hull and colleagues recruited 200 participants with cancer with acute symptomatic proximal vein thrombosis (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). Participants were randomized to receive tinzaparin 175 anti‐Xa/kg subcutaneously daily for 12 weeks or UFH either 5000 U or 80 U/kg for five days followed by VKAs (target INR 2 to 3) for 12 weeks. Assessed outcomes were mortality, recurrent VTE, major and minor bleeding, and thrombocytopenia. Participants were followed up for one year.  </p> <p>Lee and colleagues recruited 676 participants with cancer and proximal DVT, PE or both in the CLOT study (<a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>). Participants were randomized to receive dalteparin 200 IU per kilogram once daily for five to seven days and a coumarin derivative for six months (target INR 2.5) or dalteparin alone for six months (200 IU per kilogram once daily for one month, followed by a daily dose of approximately 150 IU per kilogram for five months). Assessed outcomes were mortality, recurrent VTE, and major and minor bleeding. Participants were followed up for six months.  </p> <p>Lee and colleagues recruited 900 participants with active cancer and objectively documented proximal DVT or PE in the CATCH study (<a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>). Participants were randomized to receive tinzaparin 175 IU/kg once daily for six months or conventional therapy with tinzaparin 175 IU/kg once daily for five to 10 days followed by warfarin at a dose adjusted to maintain the INR within the therapeutic range (2 to 3) for six months. Assessed outcomes were mortality, recurrent VTE, and major and non‐major bleeding. Participants were followed up for six months.  </p> <p>Lopez‐Beret and colleagues recruited 35 participants with cancer and symptomatic DVT of the lower limb, a subgroup of 158 participants recruited (Lopez‐Beret 2001a). Participants were randomized to receive nadroparin 1.025 anti‐Xa IU/10 kg twice daily for three days then 1.025 anti‐Xa IU/10 kg twice daily, after the third month, nadroparin was switched to once daily, or nadroparin 1.025 anti‐Xa IU/10 kg twice daily for three days then acenocoumarol (target INR 2 to 3) for three to six months. Assessed outcome available for the cancer subgroup was mortality. Participants were followed up for 12 months.  </p> <p>Mazilu and colleagues recruited 46 participants with paraneoplastic DVT (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). Participants were randomized to receive either fixed‐dose dabigatran or adjusted‐dose acenocoumarol. Assessed outcomes were mortality, recurrent VTE and bleeding.  </p> <p>McBane and colleagues recruited 300 participants with active cancer from 28 centers the U.S.A.(Mc Bane 2019 (ADAM‐VTE)). Participants were randomized to receive apixaban 10 mg twice daily for seven days then 5 mg twice daily for a total of six months or dalteparin 200 IU/kg for the first month and than 150 IU/kg once daily for a total of six months. Assessed outcomes were major bleeding, clinically‐relevant non‐major bleeding, any recurrence of DVT, PE, fatal PE, arterial thromboembolism and mortality.Gastrointestinal bleeding was also reported. Participants were followed up for six months. </p> <p>Meyer and colleagues recruited 146 participants with cancer and VTE (<a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>). Participants were randomized to receive enoxaparin 1.5 mg/kg daily for three months or enoxaparin 1.5 mg/kg daily for four days followed by warfarin (target INR 2 to 3) for three months. Outcomes assessed were mortality, recurrent VTE and major bleeding. Participants were followed up for three months. The study noted that 52% of participants had ongoing cancer treatment in the warfarin group versus 76% in the enoxaparin group.  </p> <p>Prins and colleagues recruited 459 participants with active cancer at baseline and DVT or PE, a subgroup of the EINSTEIN‐DVT and EINSTEIN‐PE studies (<a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>). Participants were randomized to receive rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily. Participants assigned to the enoxaparin and VKA group received enoxaparin subcutaneously 1.0 mg/kg bodyweight twice daily and either oral warfarin or acenocoumarol (target INR 2 to 3), started within 48 hours of randomization. Enoxaparin was discontinued when the INR was 2 or more for two days consecutively and the participant had received at least five days of enoxaparin treatment. The dose of the VKA was adjusted to maintain an INR of 2 to 3. Assessed outcomes were mortality, recurrent VTE, major bleeding and clinically relevant bleeding. Participants were followed up for 12 months.  </p> <p>Raskob and colleagues recruited 208 participants with active cancer and DVT or PE (<a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>). Participants were randomized to receive LMWH for at least five days followed by oral edoxaban 60 mg once daily (edoxaban group) or warfarin (or placebo) started concurrently with the study regimen of heparin. Assessed outcomes were recurrent VTE, major and non‐major bleeding, and mortality. Participants were followed up for one year.  </p> <p>Raskob and colleagues recruited 1050 participants with active cancer and VTE (<a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>). Participants were randomized to receive LMWH for at least five days followed by oral edoxaban 60 mg once daily (edoxaban group) or subcutaneous dalteparin 200 IU per kilogram bodyweight once daily for one month followed by dalteparin 150 IU per kilogram once daily (dalteparin group). Assessed outcomes were recurrent VTE, major and non‐major bleeding, and mortality. Participants were followed up for one year.  </p> <p>Romera and colleagues recruited 69 participants with cancer with symptomatic proximal DVT, a subgroup of 241 recruited participants (<a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>). All participants were given tinzaparin fixed dose 175 IU anti‐Xa per kg bodyweight once daily. The participants randomized to tinzaparin received this regimen for six months without dosage adjustments. The participants randomized to oral anticoagulants were given acenocoumarol 3 mg orally, which was subsequently adjusted to achieve a regular INR between 2 and 3 for six months. This group received tinzaparin until the INR reached at least 2 on two consecutive measurements. The assessed outcome for the cancer subgroup was recurrent VTE. Participants were followed up for one year.  </p> <p>Schulman and colleagues recruited 221 participants with active cancer and VTE, a subgroup of the RECOVER and RECOVER‐II trials (<a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>). Participants were randomized to receive warfarin adjusted to achieve an INR of 2 to 3 or dabigatran fixed‐dose 150 mg twice daily. In both randomization arms, initial treatment was with a parenteral anticoagulant (UFH, LMWH or fondaparinux) until the INR or sham INR became at least 2 for two consecutive days. Assessed outcomes were symptomatic recurrent VTE and VTE‐related death, major bleeding and clinically relevant non‐major bleeding. Participants were followed up for six months. The study authors reported complete follow‐up. </p> <p>Van Doormaal and colleagues recruited 284 participants with active cancer and DVT, a subgroup of the Van Gogh DVT trial (<a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>). Participants were randomized to receive idraparinux for three or six months or VKA. The study noted that 66% of the idraparinux group and 69% of the VKAs group had active cancer. Assessed outcomes were mortality, recurrent VTE and bleeding. Participants were followed up for six months.  </p> <p>Young and colleagues recruited 406 participants with active cancer and VTE (Young 2017 (SELECT‐D)). Participants were randomized to receive rivaroxaban 15 mg twice daily for three weeks then 20 mg once daily for a total of six months or dalteparin 200 IU/kg daily for one month and 150 IU/kg daily for a total of six months. Assessed outcomes were recurrent VTE, mortality, and major and clinically non‐major bleeding. Gastrointestinal bleeding was also reported. Participants were followed up for six months. </p> </section> <section id="CD006650-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We excluded 46reports) from this review for the following reasons: not population of interest (26);not intervention of interest (3):; not design of interest (10) and outcome data for cancer subgroup not reported (7). See <a href="./references#CD006650-sec-0121" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD006650-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>The judgments for the risk of bias are summarized in <a href="#CD006650-fig-0002">Figure 2</a> and <a href="#CD006650-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006650-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD006650-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006650-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD006650-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006650-sec-0051"> <h4 class="title">Allocation</h4> <p>Random sequence was definitely generated in 14 studies (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>;  <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>; <a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). </p> <p>Five studies were judged to be at low risk of selection bias because minimal information about random sequence generation was provided (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>). </p> <p>We judged allocation to be adequately concealed in 12 studies (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a> <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>; <a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>). Eight studies did not report allocation concealment (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>). </p> </section> <section id="CD006650-sec-0052"> <h4 class="title">Blinding</h4> <section id="CD006650-sec-0053"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We judged participants and personnel to be definitely blinded in four studies (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>),  definitely not blinded in 11 studies (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>;  <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>; <a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a> , and probably not blinded in three studies (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>). One study did not report on blinding of participants and personnel (unclear risk of bias; <a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). </p> </section> <section id="CD006650-sec-0054"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p> </p> <p>We judged outcome assessors to be definitely blinded in 10 studies (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>; <a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>), definitely not blinded in one study (<a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>), and probably not blinded in four studies (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>)  One study was not clear about the blinding of outcome assessors (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). </p> </section> </section> <section id="CD006650-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed the risk of bias associated with missing data for each outcome with a significant effect (please see <a href="#CD006650-sec-0058">Effects of interventions</a> section). Seven studies did not report follow‐up data for the cancer subgroup, but we assumed complete follow‐up taking into consideration the small sample size (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>; <a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>) ).Six studies were judged to be at low risk of incomplete outcome data because the rates of missing outcome data were lower that the event rate in the studies (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>), whereas  five studies were judged to be at high risk of incomplete outcome data because the rate of missing outcome data was higher that the event rate in the study (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>). One study reported complete follow‐up based on communication with author( <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>). The risk of incomplete outcome data was not clear in one study (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). </p> </section> <section id="CD006650-sec-0056"> <h4 class="title">Selective reporting</h4> <p>We did not suspect selective reporting of outcomes for any of the studies except for <a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a> where results for outcomes of interest were not reported individually, and all results were reported under the term "major outcome," in addition we suspected selective reporting in <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a> where authors failed to report on some of the outcomes mentioned in the study protocol. The cancer subgroup data were missing for a large number of studies. Reporting bias was not clear in one study (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>. </p> </section> <section id="CD006650-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>Another potential source of bias was the screening for asymptomatic VTE in three studies (<a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>). The full‐text of the abstract <a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a> was never published. </p> </section> </section> <section id="CD006650-sec-0058"> <h3 class="title" id="CD006650-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD006650-tbl-0001"><b>Summary of findings 1</b> Low molecular weight heparin secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</a>; <a href="./full#CD006650-tbl-0002"><b>Summary of findings 2</b> Direct oral anticoagulant secondary prophylaxis compared to Vitamin K antagonist secondary prophylaxis in patients with active cancer with venous thromboembolism</a>; <a href="./full#CD006650-tbl-0003"><b>Summary of findings 4</b> Direct oral anticoagulant secondary prophylaxis compared to Low molecular weight heparin secondary prophylaxis in patients with cancer with venous thromboembolism</a>; <a href="./full#CD006650-tbl-0004"><b>Summary of findings 5</b> Idraparinux secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</a> </p> <section id="CD006650-sec-0059"> <h4 class="title">Low molecular weight heparin versus vitamin K antagonist</h4> <p>Seven RCTs compared LMWH to VKA for the long‐term treatment of VTE in patients with cancer (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>; <a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>). The initial treatment was heparin in both arms for all the seven studies. </p> <p>We identified one ongoing study comparing LMWH to VKA for the long‐term treatment of cancer participants with VTE that was terminated due to slow inclusion of patients (<a href="./references#CD006650-bbs2-0066" title="KleinjanA , Di NisioM , KamphuisenPW , BullerHR , on behalf of the steering committee. Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism – a randomized controlled trial. 5th ICTHIC Abstracts: Poster Sessions / Thrombosis Research2010;125(PO-67):S184. ">Kamphuisen 2010 (Longheva)</a>). </p> <section id="CD006650-sec-0060"> <h5 class="title">All‐cause mortality up to six months</h5> <p>Meta‐analysis of four RCTs including 1712 participants, found that LMWH may result in little to no difference on mortality up to six months when compared to VKA (Relative Risk (RR) 0.99, 95% CI 0.88 to 1.13; Risk Difference (RD) 4 fewer per 1000, 95% CI 45 fewer to 45 more; I<sup>2</sup> 0%; low certainty evidence; <a href="./references#CD006650-fig-0004" title="">Analysis 1.1</a>) (<a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>). The certainty of evidence was rated down to low due to serious risk of bias and serious imprecision (<a href="./full#CD006650-tbl-0001">summary of findings Table 1</a>). </p> <p>The results were consistent in a sensitivity analysis including the study published as an abstract (RR 0.99, 95% CI 0.88 to 1.12) (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>),in a sensitvity analysis including the studies that did not specify whether the cancer was active in the included patients (RR 1.00, 95% CI 0.89 1.13) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0009" title="Lopez-BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77-90. ">Lopez‐Beret 2001</a>), and in a sensitivity analysis including the study that used a different initial anticoagulant in the two study arms (RR 1.00, 95% CI 0.89 to 1.12) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). </p> <p>We did not create a funnel plot for the outcome of mortality due to the low number of included trials. </p> </section> <section id="CD006650-sec-0061"> <h5 class="title">All‐cause mortality: time‐to‐event analysis</h5> <p>Two studies including 810 participants reported data allowing their inclusion in the time‐to‐event analysis (<a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>). Meta‐analysis indicated that LMWHmay reduce mortality slightly compared to VKA (HR 0.94, 95% CI 0.74 to 1.20; RD 18 fewer per 1000, 95% CI 81 fewer to 56 more; I<sup>2</sup> 16%; low certainty evidence <a href="./references#CD006650-fig-0005" title="">Analysis 1.2</a>). The certainty of evidence was rated down to low due to serious risk of bias and serious imprecision (<a href="./full#CD006650-tbl-0001">summary of findings Table 1</a>). The results were consistent in a sensitivity analysis including data provided by the author for the study that used a different initial anticoagulant in the two study arms (HR 0.96, 95% CI 0.81 to 1.14) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). </p> </section> <section id="CD006650-sec-0062"> <h5 class="title">Recurrent venous thromboembolism up to six months</h5> <p>None of the studies reported DVT and PE as separate outcomes. Meta‐analysis of four studies including 956 participants found that LMWH probably reduces recurrent VTE up to six months compared to VKA (RR 0.59, 95% CI 0.44 to 0.80; RD 51 fewer per 1000, 95% CI 69 fewer to 25 fewer; I<sup>2</sup> 0%; moderate certainty evidence; <a href="./references#CD006650-fig-0006" title="">Analysis 1.3</a>) (<a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>).The certainty of evidence was rated down to moderate due to serious risk of bias (<a href="./full#CD006650-tbl-0001">summary of findings Table 1</a>). </p> <p>The results were consistent in a sensitvity analysis including the studies that did not specify whether the cancer was active in the included patients (RR 0.59, 95% CI 0.45 to 0.79) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>) and in a sensitivity analysis including the study that used a different initial anticoagulant in the two study arms (RR 0.56, 95% CI 0.42 to 0.74) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). </p> <p>Since the primary meta‐analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing data, we conducted sensitivity meta‐analyses using the a priori plausible assumptions detailed in the <a href="#CD006650-sec-0015">Methods</a> section. The effect estimate remained significant across all four stringent assumptions (<a href="./appendices#CD006650-sec-0110">Appendix 3</a>). </p> <p>We did not create a funnel plot for the outcome of recurrent VTE due to the low number of included trials. </p> </section> <section id="CD006650-sec-0063"> <h5 class="title">Recurrent venous thromboembolism: time‐to‐event analysis</h5> <p>Two studies including 810 participants reported data allowing their inclusion in the time‐to‐event meta‐analyses. We used time‐to‐event data reported by two studies (<a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>). Meta‐analysis showed that LMWH probably reduces recurrent VTE (HR 0.49, 95% CI 0.31 to 0.78; RD 61 fewer per 1000, 95% CI 84 fewer to 26 fewer; I<sup>2</sup> 0%; moderate certainty evidence; <a href="./references#CD006650-fig-0007" title="">Analysis 1.4</a>).The certainty of evidence was rated down to moderate due to serious risk of bias (<a href="./full#CD006650-tbl-0001">summary of findings Table 1</a>). </p> <p>The results were consistent in a sensitivity analysis (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>; <a href="./references#CD006650-bbs2-0016" title="RomeraA , CairolsMA , Vila-CollR , MartíX , ColoméE , BonellA , et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349-56. Romera-VillegasA , Marti MestreX , Vila CollR , Colome NafriaE . Long-term treatment with a low-molecular-weight heparin administered subcutaneously compared with a vitamin K antagonist: subanalysis of patients with cancer. Medicina Clinica2015;144:16-20. ">Romera 2009</a>) including data provided by the author for the study that used a different initial anticoagulant in the two study arms (HR 0.47, 95% CI 0.32 to 0.71) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). </p> <p>We did not create a funnel plot for the outcome of recurrent VTE due to the low number of included trials. </p> </section> <section id="CD006650-sec-0064"> <h5 class="title">Major bleeding up to six months</h5> <p>Meta‐analysis of four studies including 1712 participants found than LMWH may result in little to no difference in major bleeding up tp six months compared to VKA (RR 1.09, 95% CI 0.55 to 2.12; RD 4 more per 1000, 95% CI 19 fewer to 48 more; I<sup>2</sup> = 46%; low certainty evidence; <a href="./references#CD006650-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>). The certainty of evidence was rated down to low due to serious risk of bias and serious imprecision (<a href="./full#CD006650-tbl-0001">summary of findings Table 1</a>). </p> <p>The results were different in a sensitivity analysis including the study published as an abstract (RR 0.85, 95% CI 0.41 to 1.74) (<a href="./references#CD006650-bbs2-0003" title="CesaroneMR , LeddaA , NicolaidesA , BelcaroG , GeroulakosG . Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation2003;108(17):2875. ">Cesarone 2003</a>) and in a senstivity analysis including the study that did not specify whether the cancer was active in the included patient and used a different initial anticoagulant in the two study arms for the outcome of major bleeding (RR 1.07, 95% CI 0.64 to 1.78) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). </p> <p>We did not create a funnel plot for the outcome of major bleeding due to the low number of included trials. </p> </section> <section id="CD006650-sec-0065"> <h5 class="title">Minor bleeding up to six months</h5> <p>Meta‐analysis of four studies including 1712 participants found than LMWH may reduce minor bleeding up tp six months compared to VKA but the evidence is very uncertain (RR 0.78, 95% CI 0.47 to 1.27; RD 38 fewer per 1000, 95% CI 92 fewer to 47 more; I<sup>2</sup> = 78%; very low certainty evidence; <a href="./references#CD006650-fig-0009" title="">Analysis 1.6</a>) (<a href="./references#CD006650-bbs2-0004" title="DeitcherSR , KesslerCM , LyonsRM , FareedJ . Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood2003;102(11):322A. DeitcherSR , KesslerCM , MerliG , RigasJ , LyonsRM , CortS . Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proceedings, annual meeting of the American Society of Clinical Oncology 22, 761-Abstract no: 30602003;1(1):OC194. DeitcherSR , KesslerCM , MerliG , RigasJR , LyonsRM , FareedJ , ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical and Applied Thrombosis/hemostasis2006;12(4):389-96. ">Deitcher 2006 (ONCENOX)</a>; <a href="./references#CD006650-bbs2-0007" title="LeeA , LevineM , BakerR , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53. LeeAY , JulianJA , LevineMN , BakerRI , BowdenC , KakkarAK , et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomised trial in cancer patients with venous thromboembolism (VTE). Proceedings, annual meeting of the American Society of Clinical Oncology2003;22:211-Abstract no: 846. LeeAY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). Journal of Thrombosis and Haemostasis2003;1:Abstract no: OC398. LeeAY , ParpiaS , JulianJ , RicklesF , PrinsM , Levine, M. Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients. Journal of Thrombosis and Haemostasis2009;7(S2):107. LeeAY , RicklesFR , JulianJA , GentM , BakerRI , BowdenC , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology2005;23(10):2123-9. LevineMN , LeeAY , BakerRI , BowdenC , KakkarAK , PrinsM , et al. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism. 2002 Blood;100:Abstract no: 298. WoodruffS , FeugereG , AbreuP , HeisslerJ , JenF . A post-HOC analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. Journal of Thrombosis and Thrombolysis2015;39(3):418. ">Lee 2003 (CLOT)</a>; <a href="./references#CD006650-bbs2-0008" title="BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al, CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism – analysis of the CATCH study. Thrombosis and Haemostasis2018;118(5):914-21. [DOI: 10.1055/s-0038-1641150]BauersachsR , LeeAY , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients – analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis2015;13:76. BauersachsR . CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. Hematology Reports2011;3:Suppl 1. KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al, CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis2018;16:1-9. [DOI: 10.1111/jth.14007]KamphuisenPW , LeeAY , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism – the CATCH study. Journal of Thrombosis and Haemostasis2015;13:182-3. KhoranaAA , BauersachsR , KamphuisenPW , MeyerG , JanasMS , JarnerMF , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference2015;33:15 Suppl 1. LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer2013;13(1):284. [NCT01130025]LeeAY , BauersachsR , JanasMS , JarnerMF , KamphuisenPW , MeyerG , et al. CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting. Journal of Clinical Oncology2012;Suppl:TPS9149. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF , et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood Conference: 56th Annual Meeting of the American Society of Hematology2014;124:21. LeeAY , KamphuisenPW , MeyerG , BauersachsR , JanasMS , JarnerMF . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA2015;314:677. ">Lee 2015 (CATCH)</a>; <a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>). The certainty of evidence was rated down to very low due to serious risk of bias, serious inconsistency, and serious imprecision (<a href="./full#CD006650-tbl-0001">summary of findings Table 1</a>). </p> <p>The results were consistent in a sensitivity analysis including the study that did not specify whether the cancer was active in the included patient and used a different initial anticoagulant in the two study arms (RR 0.84, 95% CI 0.56 to 1.27) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). </p> <p>We did not create a funnel plot for the outcome of minor bleeding due to the low number of included trials. </p> </section> <section id="CD006650-sec-0066"> <h5 class="title">Thrombocytopenia up to six months</h5> <p>One study including 138 participants assessed thrombocytopenia (<a href="./references#CD006650-bbs2-0012" title="GruelY , MeyerG , MarjanovicZ , ValckeJ , LorcerieB , Solal-CelignyP , et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood2001;98:Abstract no: 2956. MeyerG , MarjanovicZ , ValckeJ , LorcerieB , GruelY , Solal-CelignyP , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Archives of Internal Medicine2002;162(15):1729-35. ">Meyer 2002 (CANTHANOX)</a>). The study found that LMWH may reduce thrombocytopenia up to six months slightly compared to VKA (RR 0.94, 95% CI 0.52 to 1.69; RD 15 fewer per 1000, 95% CI 122 fewer to 175 more; low certainty evidence; <a href="./references#CD006650-fig-0010" title="">Analysis 1.7</a>). The certainty of evidence was rated down to low due to very serious imprecision (<a href="./full#CD006650-tbl-0001">summary of findings Table 1</a>). </p> <p>The results were consistent in a sensitivity analysis including the study that did not specify whether the cancer was active in the included patient and used a different initial anticoagulant in the two study arms (RR 1.10, 95% CI 0.67 to 1.79) (<a href="./references#CD006650-bbs2-0006" title="HullR , PineoGF , MahAF , BrantRF . A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis and Haemostasis2003;1:Abstract no: P1373a. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine2006;119(12):1062-72. HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37(1 Suppl 1):123-32. HullRD , PineoGF , BrantRF . Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical and Applied Thrombosis-Hemostasis1996;2:S4-11. ">Hull 2006 (LITE)</a>). </p> <p>We did not create a funnel plot for the outcome of thrombocytopenia due to the low number of included trials. </p> </section> <section id="CD006650-sec-0067"> <h5 class="title">Health‐related quality of life up to six months</h5> <p>None of the studies reported health‐related quality of life.</p> </section> <section id="CD006650-sec-0068"> <h5 class="title">Postphlebitic syndrome up to six months</h5> <p>None of the studies reported postphlebitic syndrome.</p> </section> </section> <section id="CD006650-sec-0069"> <h4 class="title">Direct oral anticoagulants versus vitamin K antagonists</h4> <p>Five RCTs compared DOAC to VKA for the long‐term treatment of VTE in patients with cancer (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>). The initial treatment was heparin in both arms for two studies (<a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>), DOAC vs LMWH for two other studies (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>, and DOAC vs VKA in one study (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>. </p> <section id="CD006650-sec-0070"> <h5 class="title">All‐cause mortality six to 12 months</h5> <p>Meta‐analysis of five RCTs, including 1060 participants found that DOAC may reduce mortality from six to 12 months slightly compared to VKA (RR 0.94, 95% CI 0.72 to 1.23; RD 10 fewer per 1000, 95% CI 48 fewer to 39 more; I<sup>2</sup> = 0%; low certainty evidence; <a href="./references#CD006650-fig-0011" title="">Analysis 2.1</a>) (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>). The certainty of evidence was rated down to low due to very serious imprecision (<a href="./full#CD006650-tbl-0002">summary of findings Table 2</a>). </p> <p>The results were consistent in a sensitivity analysis including the study published as an abstract and that did not specify whether the cancer was active in the included patients (RR 0.92, 95% CI 0.71 to 1.19) (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). </p> <p>We did not create a funnel plot for the outcome of all‐cause mortality due to the low number of included trials. </p> </section> <section id="CD006650-sec-0071"> <h5 class="title">Recurrent venous thromboembolism six to 12 months</h5> <p>None of the studies reported DVT and PE as separate outcomes. Meta‐analysis of four studies including 1050 participants found that DOAC may reduce recurrent VTE from six to to 12 months slightly compared to VKA (RR 0.63, 95% CI 0.34 to 1.15; RD 18 fewer per 1000, 95% CI 32 fewer to 7 more; I<sup>2</sup> = 0%, low certainty evidence; <a href="./references#CD006650-fig-0012" title="">Analysis 2.2</a>) (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>). The certainty of evidence was rated down to low due to very serious imprecision (<a href="./full#CD006650-tbl-0002">summary of findings Table 2</a>). </p> <p>We did not create a funnel plot for the outcome of recurrent VTE due to the low number of included trials. </p> </section> <section id="CD006650-sec-0072"> <h5 class="title">Major bleeding six to 12 months</h5> <p>Meta‐analysis of four studies including 1055 participants found that DOACs may result in little to no difference in major bleeding compared to VKA (RR 0.77, 95% CI 0.39 to 1.53; RD 8 fewer per 1000, 95% CI 23 fewer to 20 more; low certainty evidence; I<sup>2</sup> = 0%; <a href="./references#CD006650-fig-0013" title="">Analysis 2.3</a>) (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>).The certainty of evidence was rated down to low due to very serious imprecision (<a href="./full#CD006650-tbl-0002">summary of findings Table 2</a>). </p> <p>We did not create a funnel plot for the outcome of major bleeding due to the low number of included trials. </p> </section> <section id="CD006650-sec-0073"> <h5 class="title">Minor bleeding six to 12 months</h5> <p>Meta‐analysis of four studies including 1055 participants found that DOACs may reduce minor bleeding from six to to 12 months slightly compared to VKA (RR 0.83, 95% CI 0.57 to 1.23; RD 22 fewer per 1000, 95% CI 55 fewer to 29 more; low‐certainty evidence; <a href="./references#CD006650-fig-0014" title="">Analysis 2.4</a>) (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0017" title="SchulmanS , GoldhaberSZ , KearonC , KakkarAK , SchellongS , ErikssonH . Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis2015;114(1):150-7. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">Schulman 2015 (RECOVER I‐II)</a>). The certainty of evidence was rated down to low due to very serious imprecision (<a href="./full#CD006650-tbl-0002">summary of findings Table 2</a>). </p> <p>We did not create a funnel plot for the outcome of minor bleeding due to the low number of included trials. </p> </section> <section id="CD006650-sec-0074"> <h5 class="title">Thrombocytopenia six to 12 months</h5> <p>None of the studies reported thrombocytopenia.</p> </section> <section id="CD006650-sec-0075"> <h5 class="title">Health‐related quality of life six to 12 months</h5> <p>Two studies assessed health‐related quality of life; the first used the Anti‐Clot Treatment Scale (ACTS) (<a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>), while the other did not report the tool used for assessment (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). Prins and colleagues assessed the outcome for the study population (8485 participants) without reporting on the cancer subgroup (655 participants). They reported that HRQoL was better in the rivaroxaban‐treated participants than in the group treated with enoxaparin and VKAs (no further statistical data reported). The certainty of evidence was rated down to low due to very serious imprecision (<a href="./full#CD006650-tbl-0002">summary of findings Table 2</a>). </p> <p>The study by Mazilu and colleagues, published as an abstract, reported that HRQoL was better in the dabigatran group due to the fact that there was no need for monthly blood tests as in the acenocoumarol group (<a href="./references#CD006650-bbs2-0010" title="MaziluL , ParepaIR , SuceveanuAI , SuceveanuA , BazR , CatrinoiuD . Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research2014;103(Suppl 1):S39, P221. ">Mazilu 2014 (OVIDIUS)</a>). </p> </section> <section id="CD006650-sec-0076"> <h5 class="title">Postphlebitic syndrome</h5> <p>None of the studies reported postphlebitic syndrome.</p> </section> </section> <section id="CD006650-sec-0077"> <h4 class="title">Direct oral anticoagulants versus low molecular weight heparins</h4> <p>Five RCTs compared DOAC to LMWH for the long‐term treatment of VTE in patients with cancer (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The initial treatment was DOAC vs LMWH for four studies (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>) and heparin in both arms for one study (<a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>). </p> <p>We identified four ongoing studies comparing DOACs to LMWHs for the long‐term treatment of cancer participants with VTE;two are completed and not published yet (<a href="./references#CD006650-bbs2-0068" title="Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). Ongoing study. September 2016. Contact author for more information.">Meyer 2016 (CASTA‐DIVA)</a>; <a href="./references#CD006650-bbs2-0070" title="Direct oral anticoagulants (DOACs) versus LMWH ± warfarin for VTE in cancer (CANVAS). Ongoing study. December 2016. Contact author for more information.">Schrag 2016 (CANVAS)</a>); one is still recruiting (<a href="./references#CD006650-bbs2-0069" title="A randomized phase II study to compare the safety and efficacy of dalteparin vs. rivaroxaban for cancer-associated venous thromboembolism (PRIORITY). Ongoing study. May 2017. Contact author for more information.">Ryun Park 2017 (PRIORITY)</a>); and one ongoing study that was terminated since recruitment was not as expected (<a href="./references#CD006650-bbs2-0067" title="Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. Ongoing study. March 2016. Contact author for more information.">Karatas 2015</a>). </p> <section id="CD006650-sec-0078"> <h5 class="title">All‐cause mortality up to six months</h5> <p>Meta‐analysis of five RCTs, including 2854 participants found that DOAC may result in little to no difference in mortality up to six months compared to LMWH (RR 0.97, 95% CI 0.84 to 1.14; RD 7 fewer per 1000, 95% CI 42 fewer to 35 more; I<sup>2</sup> = 25%; low certainty evidence; <a href="./references#CD006650-fig-0015" title="">Analysis 3.1</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to low due to serious risk of bias and serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>We did not create a funnel plot for the outcome of all cause mortality due to the low number of included trials. </p> </section> <section id="CD006650-sec-0079"> <h5 class="title">Recurrent venous thromboembolism up to six months</h5> <p>Meta‐analysis of five RCTs, including 2854 participants found that DOAC may reduce recurrent VTE up to six months compared to LMWH (RR 0.63, 95% CI 0.45 to 0.88; RD 32 fewer per 1000, 95% CI 48 fewer to 10 more; I<sup>2</sup> = 18%; low certainty evidence; <a href="./references#CD006650-fig-0016" title="">Analysis 3.2</a>) ) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to low due to serious risk of bias and serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>We did not create a funnel plot for the outcome of recurrent VTE due to the low number of included trials. </p> <p>Since the primary meta‐analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta‐analyses using the a priori plausible assumptions detailed in the <a href="#CD006650-sec-0015">Methods</a> section. The effect estimate remained significant across all four stringent assumptions (<a href="./appendices#CD006650-sec-0110">Appendix 3</a>). </p> </section> <section id="CD006650-sec-0080"> <h5 class="title">Major bleeding up to six months</h5> <p>Meta‐analysis of five RCTs, including 2854 participants found that DOAC may result in little to no difference in major bleeding up to six months compared to LMWH (RR 1.20, 95% CI 0.83 to 1.73; RD 7 more per 1000, 95% CI 6 fewer to 25 more; I<sup>2</sup> = 18%; low certainty evidence; <a href="./references#CD006650-fig-0017" title="">Analysis 3.3</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to low due to serious risk of bias and serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). A subgroup analysis of participants with GI tract cancer versus participants without GI tract cancer found no subgroup difference (among people with GI tract cancer RR 1.47, 95% CI 0.76 to 2.84; among people without GI tract cancer RR 1.05, 95% CI 0.63 to 1.73) (<a href="./references#CD006650-fig-0017" title="">Analysis 3.3</a>) ((<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>;<a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). </p> <p>Meta‐analysis of four RCTs, including 1838 participants found that DOAC may result in little to no difference in major GI tract bleeding up to six months compared to LMWH (RR 1.16, 95% CI 0.62 to 2.17; RD 3 more per 1000, 95% CI 8 fewer to 23 more; I<sup>2</sup> = 0%; low certainty evidence; <a href="./references#CD006650-fig-0018" title="">Analysis 3.4</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to low due to serious risk of bias and serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>Meta‐analysis of four RCTs, including 1838 participants found that DOAC may have little to no difference in major upper GI tract bleeding up to six months compared to LMWH but the evidence is very uncertain (RR 1.18, 95% CI 0.51 to 2.76; RD 2 more per 1000, 95% CI 5 fewer to 19 more; I<sup>2</sup> = 0%; very low certainty evidence; <a href="./references#CD006650-fig-0019" title="">Analysis 3.5</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to very low due to serious risk of bias and very serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>Meta‐analysis of four RCTs, including 1838 participants found that DOAC may have little to no difference in major lower GI tract bleeding up to six months compared to LMWH but the evidence is very uncertain (RR 1.10, 95% CI 0.43 to 2.80; RD 1 more per 1000, 95% CI 5 fewer to 16 more; I<sup>2</sup> = 0%; very low certainty evidence;<a href="./references#CD006650-fig-0020" title="">Analysis 3.6</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to very low due to serious risk of bias and very serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>Meta‐analysis of four RCTs, including 1838 participants found that DOAC may have little to no difference in major non‐GI tract bleeding up to six months compared to LMWH but the evidence is very uncertain (RR 0.84, 95% CI 0.62 to 1.68; RD 3 fewer per 1000, 95% CI 11 fewer to 13 more; I<sup>2</sup> = 0%; very low certainty evidence;<a href="./references#CD006650-fig-0021" title="">Analysis 3.7</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to very low due to serious risk of bias and very serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>We did not create a funnel plot for the outcome of recurrent VTE due to the low number of included trials. </p> </section> <section id="CD006650-sec-0081"> <h5 class="title">Minor bleeding up to six months</h5> <p>Meta‐analysis of five RCTs, including 2854 participants found that DOAC probably reduces minor bleeding up to six months compared to LMWH (RR 1.58, 95% CI 1.15 to 2.16; RD 39 more per 1000, 95% CI 10 more to 78 more; I<sup>2</sup> = 23%; moderate certainty evidence; <a href="./references#CD006650-fig-0022" title="">Analysis 3.8</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>).The certainty of evidence was rated down to moderate due to serious risk of bias (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>Since the primary meta‐analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing data, we conducted sensitivity meta‐analyses using the a priori plausible assumptions detailed in the <a href="#CD006650-sec-0015">Methods</a> section. The effect estimate lost significance with RI 3 and RI 5, indicating high risk of bias associated with missing data (<a href="./appendices#CD006650-sec-0110">Appendix 3</a>). </p> <p>Meta‐analysis of two RCTs, including 1495 participants found that DOAC may have little to no difference in minor GI tract bleeding up to six months compared to LMWH but the evidence is very uncertain (RR 1.37, 95% CI 0.41 to 4.64; RD 9 more per 1000, 95% CI 15 fewer to 92 more; I<sup>2</sup> = 64%; very low certainty evidence; <a href="./references#CD006650-fig-0023" title="">Analysis 3.9</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to very low due to serious inconsistency and very serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>Meta‐analysis of two RCTs, including 1495 participants found that DOAC may have little to no difference in minor upper GI tract bleeding up to six months compared to LMWH but the evidence is very uncertain (RR 1.03, 95% CI 0.04 to 25.97; RD 0 more per 1000, 95% CI 10 fewer to 267 more; I<sup>2</sup> = 74%; very low certainty evidence; <a href="./references#CD006650-fig-0024" title="">Analysis 3.10</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to very low due to very serious inconsistency and very serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>Meta‐analysis of two RCTs, including 1495 participants found that DOAC may have little to no difference in minor lower GI tract bleeding up to six months compared to LMWH (RR 1.54, 95% CI 0.72 to 3.27; RD 8 more per 1000, 95% CI 4 fewer to 33 more; I<sup>2</sup> = 0%; low certainty evidence; <a href="./references#CD006650-fig-0025" title="">Analysis 3.11</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to low due to very serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> <p>Meta‐analysis of two RCTs, including 1495 participants found that DOAC probably increases minor non‐ GI tract bleeding up to six months compared to LMWH (RR 2.37, 95% CI 1.44 to 3.89; RD 42 more per 1000, 95% CI 18 fewer to 89 more; I<sup>2</sup> = 3%; moderate certainty evidence; <a href="./references#CD006650-fig-0026" title="">Analysis 3.12</a>) (<a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0019" title="YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2014;32(15 Suppl):TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. OC-11 – anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research2016;140:S172-3. YoungA , PhillipsJ , HancocksH , MarshallA , GrumettJ , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings2015;33(15 Suppl):TPS9642. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , HaleD , DunnJA , LymanGH , HutchinsonC , MacCallumP . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018 Jul 10 ;36(20):2017-2023. ">Young 2018 (SELECT‐D)</a>). The certainty of evidence was rated down to moderate due to serious imprecision (<a href="./full#CD006650-tbl-0003">summary of findings Table 4</a>). </p> </section> <section id="CD006650-sec-0082"> <h5 class="title">Thrombocytopenia up to six months</h5> <p>None of the studies reported thrombocytopenia.</p> </section> <section id="CD006650-sec-0083"> <h5 class="title">Health‐related quality of life up to six months</h5> <p>None of the studies reported HRQoL.</p> </section> <section id="CD006650-sec-0084"> <h5 class="title">Postphlebitic syndrome up to six months</h5> <p>None of the studies reported postphlebitic syndrome.</p> </section> </section> <section id="CD006650-sec-0085"> <h4 class="title">Once‐weekly idraparinux versus vitamin K antagonists</h4> <p>One RCT with 284 participants compared once‐weekly subcutaneous injection of idraparinux versus standard treatment (parenteral anticoagulation followed by warfarin or acenocoumarol) for three or six months (<a href="./references#CD006650-bbs2-0018" title="vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104(1):86-91. ">van Doormaal 2010 (Van Gogh DVT trial)</a>). </p> <section id="CD006650-sec-0086"> <h5 class="title">All‐cause mortality up to six months</h5> <p>The trial found thatidraparinux may reduce all‐cause mortality up to six months slightly compared to VKAs on mortality at six months (RR 1.11, 95% CI 0.78 to 1.59; RD 31 more per 1000, 95% CI 62 fewer to 167 more; low‐certainty evidence). </p> </section> <section id="CD006650-sec-0087"> <h5 class="title">Recurrent venous thromboembolism up to six months</h5> <p>The trial found that idraparinux may reduce recurrent VTE up to six months slightly compared to VKA (RR 0.46, 95% CI 0.16 to 1.32; RD 42 fewer per 1000, 95% CI 65 fewer to 25 more; low‐certainty evidence). </p> </section> <section id="CD006650-sec-0088"> <h5 class="title">Major bleeding up to six months</h5> <p>The trial found that idraparinux may result in little to no difference in major bleeding up to six months slightly compared to VKA (RR 1.11, 95% CI 0.35 to 3.56; RD 4 more per 1000, 95% CI 25 fewer to 98 more; low‐certainty evidence). </p> </section> <section id="CD006650-sec-0089"> <h5 class="title">Minor bleeding up to six months</h5> <p>The study did not report minor bleeding.</p> </section> <section id="CD006650-sec-0090"> <h5 class="title">Thrombocytopenia up to six months</h5> <p>The study did not report thrombocytopenia.</p> </section> <section id="CD006650-sec-0091"> <h5 class="title">Health‐related quality of life up to six months</h5> <p>The study did not report HRQoL.</p> </section> <section id="CD006650-sec-0092"> <h5 class="title">Postphlebitic syndrome</h5> <p>The study did not report postphlebitic syndrome.</p> <p>We did not create funnel plots due to the low number of included trials for each outcome.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006650-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006650-sec-0093"></div> <section id="CD006650-sec-0094"> <h3 class="title" id="CD006650-sec-0094">Summary of main results</h3> <p>For the long‐term treatment of VTE in people with cancer, LMWH compared to VKAmay result in little to no difference on mortality and major bleeding up to six months, probably reduces recurrent VTE up to six months, may reduce minor bleeding up tp six months but the evidence is very uncertain, and may reduce thrombocytopenia up to six months slightly. </p> <p>Direct oral anticoagulants compared to VKA may reduce mortality, recurrent VTE from six to 12 months slightly and may result in little to no difference in major bleeding compared to VKA. </p> <p>Direct oral anticoagulants compared to LMWH may result in little to no difference in mortality, major bleeding, major GI tract bleeding, up to six months, may reduce recurrent VTE up to six months, may have little to no difference in major upper GI tract bleeding, major lower GI tract bleeding, major non‐GI tract bleeding, minor GI tract bleeding, minor upper GI tract bleeding, but the evidence is very uncertain, probably reduces minor bleeding up to six months, may have little to no difference in minor lower GI tract bleeding, and probably increases minor non‐ GI tract bleeding up to six months </p> <p>Idraparinux compared to VKA may reduce all‐cause mortality, recurrent VTE, up to six months slightly, and may result in little to no difference in major bleeding up to six months slightly. </p> <p> </p> </section> <section id="CD006650-sec-0095"> <h3 class="title" id="CD006650-sec-0095">Overall completeness and applicability of evidence</h3> <p>While the reduction in VTE with LMWHs was expected to reduce thrombosis‐related mortality, this did not translate into an observed reduction in all‐cause mortality. This finding was not apparently explained by an increase in any specific‐cause mortality (e.g. fatal bleeding), but might have been due to the lack of power to detect a reduction in all‐cause mortality. Similarly, the size of the available evidence was not large enough to rule out beneficial or harmful effects for many comparisons (e.g. effects of LMWHs versus VKAs on bleeding, effects of DOACs vs VKA on bleeding, effects of DOACs vs LMWH on mortality, bleeding). </p> <p>Stratifying bleeding outcomes based on type of cancer (GI tract vs non‐GI tract) did not find any subgroup effect when comparing DOAC to LWMH. When adding patients with non‐active cancer (or unclear whether active cancer) to patients with active cancer, the results of the meta‐analyses for all studied outcomes remained unchanged. were unable to conduct subgroup analyses based on histologic type (GI tract) or stage of cancer (active) because of the lack of data DELETE ONCE CONFIRMED BY EA. In the absence of evidence for the contrary, we assumed that the results of this review applied to people with any type or stage of cancer. </p> <p>For comparisons including DOACs, four RCTs used Apixaban (<a href="./references#CD006650-bbs2-0001" title="AgnelliG , BullerH , CohenA , CurtoM , GallusA , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369(9):799-808. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology2014;30:S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. ">Agnelli 2015 (AMPLIFY)</a>; <a href="./references#CD006650-bbs2-0002" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , BecattiniC , AgnelliG . Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and haemostasis2020;Nov 17:1-9. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , ConnorsJM , FontanellaA , GussoniG , HuismanMV , LambertC . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and haemostasis 2018 Sep;118(09):1668-78. AgnelliG , BecattiniC , MeyerG , MuñozA , HuismanMV , ConnorsJM , CohenA , BauersachsR , BrennerB , TorbickiA , SueiroMR . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine 2020 Apr 23;382(17):1599-607. ">Agnelli 2020 (Caravaggio)</a>; <a href="./references#CD006650-bbs2-0005" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2020;Nov 5:1708538120971148. ">El Mokadem 2020</a>; <a href="./references#CD006650-bbs2-0011" title="McBaneRD , WysokinskiWE , Le‐RademacherJG , ZemlaT , AshraniA , TafurA , PerepuU , AndersonD , GundaboluK , KuzmaC , Perez BoteroJ . Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of thrombosis and haemostasis 2020 Feb;18(2):411-21. ">McBane 2019 (ADAM‐VTE)</a>); three RCTs used Rivaroxaban (<a href="./references#CD006650-bbs2-0013" title="Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363:2499-510. Einstein-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. PrinsMH , LensingAW , BrightonTA , LyonsRM , RehmJ , TrajanovicM , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology2014;1(1):e37-46. ">Prins 2014 (EINSTEIN)</a>; <a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>; two RCTs used Edoxaban (<a href="./references#CD006650-bbs2-0014" title="Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369:1406-15. RaskobGE , BüllerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , vanEsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ">Raskob 2016 (HOKUSAI)</a>; <a href="./references#CD006650-bbs2-0015" title="RaskobGE , vanEsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study (LBA-6). In: Blood. 2017. ">Raskob 2018 (HOKUSAI)</a>) raskob 2016 2018 ; dabigatran mazilu schulman we were unable to conduct subgroup analyses based on different agents and hence we cannot make any judgment in related to class effect. The majority of studies used Apixaban CHARBEL, SOME LITERATURE ON CLASS EFFECT </p> <p>majority of stufies used apixaban ‐ unclear evidence regarding edoaxaban or other classess of DPAC </p> </section> <section id="CD006650-sec-0096"> <h3 class="title" id="CD006650-sec-0096">Quality of the evidence</h3> <p>Our systematic approach to searching, study selection and data extraction should have minimized the likelihood of missing relevant studies. </p> <p>When comparing LMWHs to VKAs, we judged the certainty of evidence to be moderate for recurrent VTE due to serious risk of bias, and moderate for mortality at one year, and major bleeding due to both imprecision and risk of bias and low for minor bleeding due to imprecision, risk of bias and inconsistency.. </p> <p>We downgraded recurrent VTE by one level due to serious risk of bias, allocation concealment unclear in two studies, high risk of selective reporting and high risk of incomplete outcome data in one study, and lack of blinding of participants and personnel in all included studies. We downgraded the outcomes of mortality and major bleeding by one level due to both risk of bias and imprecision, in addition we downgraded the outcome of minor bleed by two levels, one for inconsistency and one for risk of bias and imprecision combined. The lack of allocation concealment in two of the studies did not affect the results when conducting a sensitivity analysis after removing those studies that had a combined weight of 6.5%, but we were concerned about the lack of blinding of participants and personnel in all included studies in addition to high risk of bias in the CATCH trial that represented 43.1% of the weight, so we decided to downgrade by one level due to both concerns about imprecision and risk of bias. </p> <p>When comparing DOACs to VKAs, we judged the certainty of evidence to be moderate for HRQoL due to serious indirectness, low for mortality, recurrent VTE, and major and minor bleeding due to serious imprecision and serious indirectness. </p> <p>When comparing DOACs to LMWHs, we judged the certainty of evidence to be low for mortality, VTE recurrence, and major and minor bleeding due to serious risk of bias and serious imprecision. </p> <p>When comparing idraparinux to VKAs, we judged the certainty of evidence to be moderate for mortality due to serious imprecision and low for recurrent VTE and major bleeding due to very serious imprecision, Taking into consideration the wide CIs, the low number of events and the fact that only one study is providing data for this comparison.pote </p> </section> <section id="CD006650-sec-0097"> <h3 class="title" id="CD006650-sec-0097">Potential biases in the review process</h3> <p>The inclusion of different types of cancer in the same study precluded us from conducting the subgroup analyses to explore effect modifiers such as type and stage of cancer. The interpretation of findings was also limited by not including data from the trials published as abstracts only. A potential bias of our review might be the limitation of the electronic search strategy to participants with cancer, while the data needed for this review came from studies not restricted to this subgroup. Also, there might be potential bias associated with multiple testing in the planned meta‐analyses and currently there are no plans to adjust meta‐analyses for multiple testing. A major limitation of this review was that we were unable to include in the meta‐analyses 11 eligible RCTs with subgroups of participants with cancer because relevant data were not reported and not obtainable from the authors. </p> </section> <section id="CD006650-sec-0098"> <h3 class="title" id="CD006650-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>We identified seven published systematic reviews comparing LMWHs or DOACs to VKAs in the long‐term treatment of VTE (<a href="./references#CD006650-bbs2-0078" title="ContiS , GuerciniF , IorioA . Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiology of Haemostasis &amp; Thrombosis2003;33(4):197-201.">Conti 2003</a>; Iorio 2003; <a href="./references#CD006650-bbs2-0094" title="LaporteS , LiotierJ , BertolettiL , KleberFX , PineoGF , ChapelleC , et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. Thrombosis and Haemostasis2011;9(3):464-72.">Laporte 2011</a>; <a href="./references#CD006650-bbs2-0096" title="NobleSI , ShelleyMD , ColesB , WilliamsSM , WilcockA , JohnsonMJ . Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet2008;9(6):577-84.">Noble 2008</a>; <a href="./references#CD006650-bbs2-0098" title="PoschF , KönigsbrüggeO , ZielinskiC , PabingerI , AyC . Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thrombosis Research2015;136(3):582-9.">Posch 2015</a>; <a href="./references#CD006650-bbs2-0100" title="Romera-VillegasA , Cairols-CastelloteMA , Vila-CollR , Martí-MestreX , ColoméE , IguazI . Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Annals of Vascular Surgery2010;24(5):628-39.">Romera‐Villegas 2010</a>; <a href="./references#CD006650-bbs2-0108" title="VedovatiMC , GerminiF , AgnelliG , BecattiniC . Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest Journal2015;147(2):475-83.">Vedovati 2015</a>). We review below the findings of the two most recent reviews. </p> <p>Posch and colleagues compared LMWHs or DOACs to VKAs for the long‐term treatment of VTE in participants with cancer including six RCTs comparing LMWHs to VKAs and four RCTs comparing DOACs to VKAs (<a href="./references#CD006650-bbs2-0098" title="PoschF , KönigsbrüggeO , ZielinskiC , PabingerI , AyC . Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thrombosis Research2015;136(3):582-9.">Posch 2015</a>). The meta‐analysis found a significant reduction of recurrent VTE in favor of LMWHs (RR 0.6, 95% CI 0.45 to 0.79) and a non‐significant difference in major bleeding episodes (RR 1.07, 95% CI 0.66 to 1.73; p = 0.80). There was no significant difference in recurrent VTE and major bleeding when comparing DOACs to VKAs (recurrent VTE: RR 0.65, 95% CI 0.38 to 1.09; major bleeding: RR 0.72, 95% CI 0.39 to 1.35). These results were in agreement with our study. </p> <p>Vedovati and colleagues compared DOACs to VKAs in the long‐term treatment of VTE in participants with cancer (<a href="./references#CD006650-bbs2-0108" title="VedovatiMC , GerminiF , AgnelliG , BecattiniC . Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest Journal2015;147(2):475-83.">Vedovati 2015</a>). Meta‐analysis of five RCTs showed no significant difference in VTE recurrence when comparing DOACs to VKAs (RR 0.63, 95% CI 0.37 to 1.1). These results were in agreement with our study. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006650-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006650-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD006650-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD006650-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 1: All‐cause mortality (up to 6 months) (main analysis ‐ active cancer)" data-id="CD006650-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 1: All‐cause mortality (up to 6 months) (main analysis ‐ active cancer) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 2: All‐cause mortality (time‐to‐event)" data-id="CD006650-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 2: All‐cause mortality (time‐to‐event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 3: Recurrent venous thromboembolism (up to 6 months) (main analysis ‐ active cancer)" data-id="CD006650-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 3: Recurrent venous thromboembolism (up to 6 months) (main analysis ‐ active cancer) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 4: Recurrent venous thromboembolism (time‐to‐event)" data-id="CD006650-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 4: Recurrent venous thromboembolism (time‐to‐event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 5: Major bleeding (up to 6 months) (main analysis ‐ active cancer)" data-id="CD006650-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 5: Major bleeding (up to 6 months) (main analysis ‐ active cancer) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 6: Minor bleeding (up to 6 months) (main analysis ‐ active cancer)" data-id="CD006650-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 6: Minor bleeding (up to 6 months) (main analysis ‐ active cancer) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 7: Thrombocytopenia (up to 6 months) (main analysis‐ active cancer)" data-id="CD006650-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA), Outcome 7: Thrombocytopenia (up to 6 months) (main analysis‐ active cancer) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 1: All‐cause mortality (6‐12 months)" data-id="CD006650-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 1: All‐cause mortality (6‐12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 2: Recurrent venous thromboembolism (6‐12 months)" data-id="CD006650-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 2: Recurrent venous thromboembolism (6‐12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 3: Major bleeding (6‐12 months)" data-id="CD006650-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 3: Major bleeding (6‐12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 4: Minor bleeding (6‐12 months)" data-id="CD006650-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA), Outcome 4: Minor bleeding (6‐12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 1: All‐cause mortality (6 months)" data-id="CD006650-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 1: All‐cause mortality (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 2: Recurrent VTE (6 months)" data-id="CD006650-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 2: Recurrent VTE (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 3: Major bleeding (6 months)" data-id="CD006650-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 3: Major bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 4: Major GI bleeding (6 months)" data-id="CD006650-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 4: Major GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 5: Major upper GI bleeding (6 months)" data-id="CD006650-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 5: Major upper GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 6: Major lower GI bleeding (6 months)" data-id="CD006650-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 6: Major lower GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 7: Major non‐GI bleeding (6 months)" data-id="CD006650-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 7: Major non‐GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 8: Minor bleeding (6 months)" data-id="CD006650-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 8: Minor bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 9: Minor GI bleeding (6 months)" data-id="CD006650-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 9: Minor GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 10: Minor upper GI bleeding (6 months)" data-id="CD006650-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 10: Minor upper GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 11: Minor lower GI bleeding (6 months)" data-id="CD006650-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 11: Minor lower GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 12: Minor non‐GI bleeding (6 months)" data-id="CD006650-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH), Outcome 12: Minor non‐GI bleeding (6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 1: All‐cause mortality (up to 6 months)" data-id="CD006650-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 1: All‐cause mortality (up to 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 2: Recurrent VTE (up to 6 months)" data-id="CD006650-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 2: Recurrent VTE (up to 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 3: Major bleeding (up to 6 months)" data-id="CD006650-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 3: Major bleeding (up to 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006650-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/urn:x-wiley:14651858:media:CD006650:CD006650-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 4: Minor bleeding (up to 6 months)" data-id="CD006650-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_t/tCD006650-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Idraparinux versus vitamin K antagonists (VKA), Outcome 4: Minor bleeding (up to 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/media/CDSR/CD006650/image_n/nCD006650-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006650-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low molecular weight heparin secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low molecular weight heparin secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in patients with cancer with venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> People with cancer with venous thromboembolism<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> LMWH secondary prophylaxis<br/><b>Comparison:</b> VKA secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with VKA secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with LMWH secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.88 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>374 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 fewer per 1,000<br/>(45 fewer to 45 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (time‐to‐event)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1243<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.74 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>374 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1,000<br/>(81 fewer to 56 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.44 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 fewer per 1,000<br/>(69 fewer to 25 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism (time‐to‐event)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1243<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.49<br/>(0.31 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 fewer per 1,000<br/>(84 fewer to 26 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/>(0.55 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1,000<br/>(19 fewer to 48 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding (main analysis ‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1712<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.47 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 fewer per 1,000<br/>(92 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thrombocytopenia (main analysis‐ active cancer)<br/>follow up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>138<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.52 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1,000<br/>(122 fewer to 175 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to serious risk of bias (allocation concealment unclear in one study, lack of blinding of participants and personnel in all the four studies, high risk of incomplete outcome data in one study, and high risk of selective reporting in one study). </p> <p><sup>2</sup> Downgraded by one level due to serious imprecision. Confidence interval includes suggests both potential harm and potential benefit. </p> <p><sup>3</sup> Some concern with lack of blinding of patients and personnel. </p> <p><sup>4</sup> Some concern with inconsistency. I2= 46% </p> <p><sup>5</sup> Downgraded by one level due to serious inconsistency (I2= 78%) </p> <p><sup>6</sup> Downgraded by two levels due to very serious imprecision. Confidence interval includes suggests both potential harm and potential benefit. Low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Low molecular weight heparin secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006650-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Direct oral anticoagulant secondary prophylaxis compared to Vitamin K antagonist secondary prophylaxis in patients with active cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Direct oral anticoagulant secondary prophylaxis compared to Vitamin K antagonist secondary prophylaxis in patients with active cancer with venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population:</b> patients with active cancer with venous thromboembolism<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> DOAC secondary prophylaxis<br/><b>Comparison:</b> VKA secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Vitamin K antagonist (VKA) secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Direct oral anticoagulant (DOAC) secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1060<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.72 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 fewer per 1,000<br/>(48 fewer to 39 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1050<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.34 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1,000<br/>(32 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1055<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/>(0.39 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1,000<br/>(23 fewer to 20 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1055<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.57 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 fewer per 1,000<br/>(55 fewer to 29 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health related quality of life<br/>follow up: range 3 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8485<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Prins 2014 (EINSTEIN DVT‐PE; n=8485 ): "in the general population of the EINSTEIN studies, patient‐reported satisfaction and quality of life was better in the rivaroxaban‐treated patients than in the group treated with enoxaparin and vitamin K antagonist, although we have not yet examined whether this is the same in patients with active cancer. Hence, it can be expected that quality of life will also be improved with rivaroxaban compared with long‐term injected low molecular‐weight heparin." The tool used was validated measure of treatment satisfaction – the Anti‐Clot Treatment Scale (ACTS)) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Some concern with indirectness (study by Schulman et al (RECOVER I‐II) included patients with a diagnosis of cancer within five years before enrollment), however the weight of these studies was low and heterogeneity was very low. </p> <p><sup>2</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit and potential harm. </p> <p><sup>3</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit and potential no effect. Low number of events. </p> <p><sup>4</sup> Downgraded by one level for serious indirectness. The study by Prins and colleagues (Prins 2014 ( EINSTEIN n=8485)) reports health related quality of life for the whole study population, without providing data for the cancer subgroup </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Direct oral anticoagulant secondary prophylaxis compared to Vitamin K antagonist secondary prophylaxis in patients with active cancer with venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006650-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Direct oral anticoagulant secondary prophylaxis compared to Low molecular weight heparin secondary prophylaxis in patients with cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Direct oral anticoagulant secondary prophylaxis compared to Low molecular weight heparin secondary prophylaxis in patients with cancer with venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with cancer with venous thromboembolism<br/><b>Setting:</b> Outpatient<br/><b>Intervention:</b> DOAC secondary prophylaxis<br/><b>Comparison:</b> LMWH secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Low molecular weight heparin (LMWH) secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Direct oral anticoagulant (DOAC) secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2854<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.83 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1,000<br/>(42 fewer to 35 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2854<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.45 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 fewer per 1,000<br/>(48 fewer to 10 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2994<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/>(0.83 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1,000<br/>(6 fewer to 25 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/>(0.62 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 more per 1,000<br/>(8 fewer to 23 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major upper GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/>(0.51 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1,000<br/>(5 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major lower GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(0.43 to 2.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more per 1,000<br/>(5 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major non‐GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1838<br/>(4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/>(0.42 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1,000<br/>(11 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2854<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.58<br/>(1.15 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 more per 1,000<br/>(10 more to 78 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>6 7 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/>(0.41 to 4.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1,000<br/>(15 fewer to 92 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor upper GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>6 7 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/>(0.04 to 25.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1,000<br/>(10 fewer to 267 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor lower GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54<br/>(0.72 to 3.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 more per 1,000<br/>(4 fewer to 33 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor non‐GI bleeding<br/>follow up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1495<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>7 10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.37<br/>(1.44 to 3.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 more per 1,000<br/>(14 more to 89 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to serious risk of bias. Allocation concealment was not reported in one study, lack of blinding of patients and personnel in all studies, and high risk of bias related to incomplete outcome data. </p> <p><sup>2</sup> Downgraded by one level due to serious imprecision. Confidence interval suggests both potential benefit and potential harm. </p> <p><sup>3</sup> Downgraded by one level due to serious imprecision. Confidence interval suggests both potential benefit and potential no effect. </p> <p><sup>4</sup> Downgraded by one level due to serious imprecision. Confidence interval suggests both potential harm and potential no effect. </p> <p><sup>5</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential harm and potential no effect. Low number of events. </p> <p><sup>6</sup> Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential harm and potential benefit. Low number of events. </p> <p><sup>7</sup> Some concern with risk of bias. Lack of blinding of patients and personnel in both studies. </p> <p><sup>8</sup> Downgraded by one level due to serious inconsistency (unexplained heterogeneity I2=64%) and due to some concern with risk of bias. </p> <p><sup>9</sup> Downgraded by two levels due to very serious inconsistency (unexplained heterogeneity I2=74%.) and due to some concern with risk of bias. </p> <p><sup>10</sup> Downgraded by one level due to serious imprecision. Low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Direct oral anticoagulant secondary prophylaxis compared to Low molecular weight heparin secondary prophylaxis in patients with cancer with venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006650-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Idraparinux secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Idraparinux secondary prophylaxis compared to VKA secondary prophylaxis in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Population</b>: people with cancer with VTE receiving secondary prophylaxis </p> <p><b>Setting</b>: outpatient </p> <p><b>Intervention</b>: idraparinux prophylaxis </p> <p><b>Control</b>: VKA prophylaxis </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with VKA secondary prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with idraparinux secondary prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>284<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b><br/>(0.78 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 more per 1000<br/>(62 fewer to 167 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b><br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>270<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.46</b><br/>(0.16 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 fewer per 1000<br/>(65 fewer to 25 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b><br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>270<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.11</b><br/>(0.35 to 3.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(25 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> – not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI) </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>VKA:</b> vitamin K antagonist; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious imprecision, 95% CI was consistent with the possibility for important benefit (62 per 1000 absolute reduction) and possibility of important harm (167 per 1000 absolute increase), included 85 events. </p> <p><sup>b</sup>Downgraded two level due to very serious imprecision, 95% CI was consistent with the possibility of important benefit (65 fewer per 1000) and possibility of important harm (25 more per 1000); included 15 events. </p> <p><sup>c</sup>Downgraded two levels due to very serious imprecision, 95% CI was consistent with the possibility for important benefit (25 per 1000 absolute reduction) and possibility of important harm (98 per 1000 absolute increase), included 11 events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Idraparinux secondary prophylaxis compared to vitamin K antagonist secondary prophylaxis in people with cancer with venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006650-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A therapy given in addition to the primary treatment to decrease the risk of the cancer recurrence or to assist in the cure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of hindering the clotting of blood especially by treatment with an anticoagulant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antithrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Used against or tending to prevent thrombosis (clotting)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct oral anticoagulants (DOAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also known as NOACs are anticoagulant medications that require less monitoring compared to the traditional anticoagulants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (as swelling and pain) and that is potentially life‐threatening if dislodgment of the thrombus results in pulmonary embolism. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fondaparinux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An anticoagulant medication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hemostatic system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The system that shortens the clotting time of blood and stops bleeding.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. 2 forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impedance plethysmography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kappa statistic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A measure of degree of nonrandom agreement between observers, measurements of a specific categorical variable, or both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metastasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The spread of a cancer cells from the initial or primary site of disease to another part of the body. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parenteral nutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The practice of feeding a person intravenously, circumventing the gastrointestinal tract. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Embolism of a pulmonary artery or one of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing, chest pain, fainting, rapid heart rate, cyanosis, shock and sometimes death. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent decrease in the number of blood platelets that is often associated with hemorrhagic conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The formation or presence of a blood clot within a blood vessel.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticoagulant medications. Warfarin is a vitamin K antagonist.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An anticoagulant medication that is a vitamin K antagonist that is used for anticoagulation.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/full#CD006650-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006650-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality (up to 6 months) (main analysis ‐ active cancer) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality (time‐to‐event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Recurrent venous thromboembolism (up to 6 months) (main analysis ‐ active cancer) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.44, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Recurrent venous thromboembolism (time‐to‐event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.31, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Major bleeding (up to 6 months) (main analysis ‐ active cancer) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.55, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Minor bleeding (up to 6 months) (main analysis ‐ active cancer) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.47, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Thrombocytopenia (up to 6 months) (main analysis‐ active cancer) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.52, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Low molecular weight heparins (LMWH) versus vitamin K antagonists (VKA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006650-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality (6‐12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.72, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Recurrent venous thromboembolism (6‐12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.34, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Major bleeding (6‐12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.39, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Minor bleeding (6‐12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006650-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause mortality (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.83, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Recurrent VTE (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Major bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.83, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 GI tract cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.76, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Non‐GI tract cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.63, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 GI tract cancer not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Major GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.62, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Major upper GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.51, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Major lower GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.43, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Major non‐GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.42, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Minor bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.15, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Minor GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.41, 4.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Minor upper GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.04, 25.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Minor lower GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.72, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Minor non‐GI bleeding (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.44, 3.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Direct oral anticoagulants (DOAC) versus low molecular weight heparins (LMWH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006650-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Idraparinux versus vitamin K antagonists (VKA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All‐cause mortality (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.78, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Recurrent VTE (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.16, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Major bleeding (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.35, 3.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Minor bleeding (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.30, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Idraparinux versus vitamin K antagonists (VKA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006650.pub5/references#CD006650-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006650.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006650-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006650-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006650-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ko#CD006650-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD006650-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006650-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006650\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006650\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006650\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006650\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006650\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006650.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006650.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006650.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006650.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006650.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718794376"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006650.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718794380"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006650.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd908ef69935f',t:'MTc0MDcxODc5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 